

CITATION REPORT

List of articles citing

Alzheimer's disease drug-development pipeline: few candidates, frequent failures

DOI: 10.1186/alzrt269

Alzheimer's Research and Therapy, 2014, 6, 37.

Source: <https://exaly.com/paper-pdf/59392587/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1260	Polyadenylation of nascent RNA during the embryogenesis of <i>Ilyanassa obsoleta</i> . 1975 , 95, 263-8		8
1259	Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. 2015 , 22, 373-404		220
1258	The significance of meaning: why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it?. 2014 , 55, 438-56		104
1257	The need for better AD animal models. 2014 , 5, 227		9
1256	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. 2014 , 10, S430-52		57
1255	Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. 2014 , 5, 252		31
1254	Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches. 2014 , 29, 1419-28		35
1253	Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning. 2014 , 9, 1265-79		1
1252	[Pharmacological superiority of nobiletin-rich <i>Citrus reticulata</i> peel, a multicomponent drug, over nobiletin alone regarding anti-dementia action]. 2015 , 145, 229-33		1
1251	Projecting Burden of Dementia in Spain, 2010-2050: Impact of Modifying Risk Factors. 2015 , 48, 721-30		19
1250	Multiple Ligands Targeting Cholinesterases and β Amyloid: Synthesis, Biological Evaluation of Heterodimeric Compounds with Benzylamine Pharmacophore. 2015 , 348, 556-63		11
1249	The need for thorough phase II studies in medicines development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2015 , 7, 67	9	16
1248	Prolonged In Vivo Retention of a Cathepsin D Targeted Optical Contrast Agent in a Mouse Model of Alzheimer's Disease. 2015 , 48, 73-87		7
1247	Closing the gap between brain banks and proteomics to advance the study of neurodegenerative diseases. 2015 , 9, 832-7		4
1246	Pharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive Tools. 2015 , 7, 3179-209		51
1245	Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. 2015 , 7, 52		426
1244	Outcomes of a multimodal cognitive and physical rehabilitation program for persons with mild dementia and their caregivers: a goal-oriented approach. 2015 , 10, 1687-94		27

1243	Proteomics in Traditional Chinese Medicine with an Emphasis on Alzheimer's Disease. 2015 , 2015, 393510	8
1242	The emerging role of bexarotene in the treatment of Alzheimer's disease: current evidence. 2015 , 11, 311-5	33
1241	The role of DNA base excision repair in brain homeostasis and disease. 2015 , 32, 172-179	23
1240	Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models. 2015 , 30, 138-65	51
1239	Approaches for discovering anti-prion compounds: lessons learned and challenges ahead. 2015 , 10, 389-97	23
1238	Do We Try Mending Humpty Dumpty or Prevent His Fall? An Alzheimer's Disease Dilemma. 2015 , 46, 289-96	0
1237	Worries about getting Alzheimer's: who's concerned?. 2015 , 30, 591-8	46
1236	Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease. 2015 , 12, 132-42	41
1235	Isoindoline-1,3-dione derivatives targeting cholinesterases: design, synthesis and biological evaluation of potential anti-Alzheimer's agents. 2015 , 23, 1629-37	37
1234	Alzheimer's Disease Tomorrow. 2015 , 129-139	
1233	DNA polymerase β deficiency leads to neurodegeneration and exacerbates Alzheimer disease phenotypes. 2015 , 43, 943-59	75
1232	A collaborative pipeline. 2015 , 18, 1	83
1231	Slowing the progression of Alzheimer's disease; what works?. 2015 , 23, 193-209	57
1230	Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). 2015 , 11, 840-9	8
1229	The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding. 2015 , 11, 823-31	41
1228	3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1/GSK-3 β Fragment Hits against Alzheimer's Disease. 2015 , 6, 1665-82	47
1227	Advances in the prevention of Alzheimer's Disease. 2015 , 7, 50	60
1226	Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States. 2015 , 37, 1652-60	4

1225	Modulation of mitochondrial complex I activity averts cognitive decline in multiple animal models of familial Alzheimer's Disease. 2015 , 2, 294-305	54
1224	2015 Alzheimer's disease facts and figures. 2015 , 11, 332-84	1212
1223	Memantine extended release (28 mg once daily): a review of its use in Alzheimer's disease. 2015 , 75, 887-97	13
1222	Regulation of copper and iron homeostasis by metal chelators: a possible chemotherapy for Alzheimer's disease. 2015 , 48, 1332-9	139
1221	From Neurodegeneration to Brain Health: An Integrated Approach. 2015 , 46, 271-83	5
1220	Can we influence the epidemiology of dementia? Perspectives from population-based studies. 2015 , 91, 651-4	10
1219	Benefits and risks of add-on therapies for Alzheimer's disease. 2015 , 5, 445-62	3
1218	Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease. 2015 , 112, E5844-53	58
1217	14th Annual Meeting of the Safety Pharmacology Society: Threading through peripheral and central nervous system presentations. 2015 , 75, 143-57	2
1216	Post-mortem brain analyses of the Lothian Birth Cohort 1936: extending lifetime cognitive and brain phenotyping to the level of the synapse. 2015 , 3, 53	19
1215	Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success. 2015 , 37, 1632-42	29
1214	Predicting targets of compounds against neurological diseases using cheminformatic methodology. 2015 , 29, 183-98	14
1213	Modulators of Amyloid β Protein (A β) Self-Assembly. 2016 , 97-191	5
1212	Cortical Amyloid Burden Differences Across Empirically-Derived Mild Cognitive Impairment Subtypes and Interaction with APOE e4 Genotype. 2016 , 52, 849-61	43
1211	Technological Peer Pressure and Product Disclosure. 2016 ,	
1210	Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. 2016 , 7, 38999-39016	42
1209	Overview of Alzheimer's Disease and Some Therapeutic Approaches Targeting A β by Using Several Synthetic and Herbal Compounds. 2016 , 2016, 7361613	82
1208	Astrocyte Differentiation of Human Pluripotent Stem Cells: New Tools for Neurological Disorder Research. 2016 , 10, 215	86

1207	Visual and Ocular Manifestations of Alzheimer's Disease and Their Use as Biomarkers for Diagnosis and Progression. 2016 , 7, 55	90
1206	New Drugs from Marine Organisms in Alzheimer's Disease. 2015 , 14, 5	41
1205	Synthesis, Molecular Modelling and Biological Evaluation of Novel Heterodimeric, Multiple Ligands Targeting Cholinesterases and Amyloid Beta. 2016 , 21, 410	23
1204	Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer's Disease. 2016 , 21, 466	64
1203	Special Issue: "Molecules against Alzheimer". 2016 , 21,	2
1202	BBB-Permeable, Neuroprotective, and Neurotrophic Polysaccharide, Midi-GAGR. 2016 , 11, e0149715	9
1201	Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease. 2016 , 7, 134	27
1200	Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies. 2016 , 139 Suppl 2, 224-236	15
1199	The amyloid cascade hypothesis: are we poised for success or failure?. 2016 , 139 Suppl 2, 237-252	235
1198	HtrA1 Proteolysis of ApoE In Vitro Is Allele Selective. 2016 , 138, 9473-8	28
1197	Active immunization therapies for Parkinson's disease and multiple system atrophy. 2016 , 31, 214-24	54
1196	Cytosolic aspartate aminotransferase, a direct binding protein of kamikihito, regulates axon growth. 2016 , 3, 41-49	2
1195	Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. 2016 , 52, 561-72	31
1194	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team. 2017 , 55, 19-35	29
1193	HMGB1 and thrombin mediate the blood-brain barrier dysfunction acting as biomarkers of neuroinflammation and progression to neurodegeneration in Alzheimer's disease. 2016 , 13, 194	114
1192	Vascular biomarkers to predict response to exercise in Alzheimer's disease: the study protocol. 2016 , 6, e011054	2
1191	Integrated Analysis of Alzheimer's Disease and Schizophrenia Dataset Revealed Different Expression Pattern in Learning and Memory. 2016 , 51, 417-25	17
1190	Cognitive-Enhancing Effects of a Polyphenols-Rich Extract from Fruits without Changes in Neuropathology in an Animal Model of Alzheimer's Disease. 2017 , 55, 115-135	33

1189	Multi-scale Modeling of Drug Action in the Nervous System. 2016 , 305-324	
1188	Early detection of cryptic memory and glucose uptake deficits in pre-pathological APP mice. 2016 , 7, 11761	10
1187	Computational Drug Networks: a computational approach to elucidate drug mode of action and to facilitate drug repositioning for neurodegenerative diseases. 2016 , 19, 11-17	3
1186	Breakdown of the Cerebrovasculature and Blood-Brain Barrier: A Mechanistic Link Between Diabetes Mellitus and Alzheimer's Disease. 2016 , 54, 445-56	33
1185	The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer's Disease. 2016 , 27-85	14
1184	New Genetic Approaches to AD: Lessons from APOE-TOMM40 Phylogenetics. 2016 , 16, 48	21
1183	Tacrine-allyl/propargylcysteine/benzothiazole trihybrids as potential anti-Alzheimer's drug candidates. 2016 , 6, 53519-53532	21
1182	References. 2016 , 353-428	
1181	Interaction of the N-Acetyl-Lysine (K13)NH ₂ segment of the beta amyloid peptide with beta-sheet-blocking peptides: site and edge specificity. 2016 , 94, 583-592	5
1180	The ALFA project: A research platform to identify early pathophysiological features of Alzheimer's disease. 2016 , 2, 82-92	63
1179	Recent progress in multifunctional metal chelators as potential drugs for Alzheimer's disease. 2016 , 327-328, 287-303	85
1178	From Companion Diagnostics to Theranostics: A New Avenue for Alzheimer's Disease?. 2016 , 59, 7759-70	31
1177	Clinical Trials in Neurodegeneration. 2016 , 289-303	
1176	2016 Alzheimer's disease facts and figures. 2016 , 12, 459-509	1615
1175	Synaptic pathology: A shared mechanism in neurological disease. 2016 , 28, 72-84	86
1174	Elucidating the link between the modifiable risk factors of Alzheimer's disease and neuroinflammation. 2016 , 6, 375-84	4
1173	The Complex Role of Apolipoprotein E in Alzheimer's Disease: an Overview and Update. 2016 , 60, 325-335	41
1172	Computational Modeling of BACE1 (BACE-1) Inhibitors Using Ligand Based Approaches. 2016 , 56, 1936-1949	85

1171	Amyloid- β -containing isoaspartate 7 as potential biomarker and drug target in Alzheimer's disease. 2016 , 26, 269-275	23
1170	Opportunities and challenges in modeling human brain disorders in transgenic primates. 2016 , 19, 1123-30	74
1169	Alzheimer's drug-development pipeline: 2016. 2016 , 2, 222-232	76
1168	The antibody aducanumab reduces A β plaques in Alzheimer's disease. 2016 , 537, 50-6	1419
1167	Development of Multifunctional Pyrimidinylthiourea Derivatives as Potential Anti-Alzheimer Agents. 2016 , 59, 8326-44	51
1166	Microbes and Alzheimer's Disease. 2016 , 51, 979-84	320
1165	Hydrogen sulfide ameliorates learning memory impairment in APP/PS1 transgenic mice: A novel mechanism mediated by the activation of Nrf2. 2016 , 150-151, 207-216	47
1164	Drug development in Alzheimer's disease: the path to 2025. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 39	9 234
1163	Drug treatments in Alzheimer's disease. 2016 , 16, 247-53	176
1162	Neurodegeneration: From cellular concepts to clinical applications. 2016 , 8, 364ps18	40
1161	Advances in A β plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease. 2016 , 6, 491-497	2
1160	Guidelines to improve animal study design and reproducibility for Alzheimer's disease and related dementias: For funders and researchers. 2016 , 12, 1177-1185	14
1159	Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge. 2016 , 12, 1014-1021	54
1158	Targeting A β Receptors to Modify Alzheimer's Disease Progression. 2016 , 227-250	
1157	Symptomatic Cognitive Enhancing Agents. 2016 , 459-475	3
1156	Molecular Imaging in Alzheimer Clinical Trials. 2016 , 523-563	
1155	Genetic variants in Alzheimer disease - molecular and brain network approaches. 2016 , 12, 413-27	71
1154	Pharmacogenetic considerations in the treatment of Alzheimer's disease. 2016 , 17, 1041-74	31

1153	Ethical considerations and challenges in first-in-human research. 2016 , 177, 6-18		2
1152	Comprehensive Geriatric Care: Effectiveness as Well as Efficacy. 2016 , 17, 14-5		
1151	Active Immunization Against the Amyloid- β Peptide. 2016 , 19-35		
1150	Cholinesterase inhibitory activity of chlorophenoxy derivatives-Histamine H3 receptor ligands. 2016 , 26, 4140-5		16
1149	Double-blind, placebo-controlled, proof-of-concept trial of bexarotene X in moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 4	9	104
1148	Quantitative characterization of brain β amyloid in 718 normal subjects using a joint PiB/FDG PET image histogram. 2016 ,		
1147	Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents. 2016 , 59, 6791-806		63
1146	The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease. 2016 , 53, 905-931		61
1145	Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. 2016 , 11, 5		28
1144	Cardanol-derived AChE inhibitors: Towards the development of dual binding derivatives for Alzheimer's disease. 2016 , 108, 687-700		66
1143	Adipocyte-derived factors in age-related dementia and their contribution to vascular and Alzheimer pathology. 2016 , 1862, 966-74		21
1142	Leptin Dysfunction and Alzheimer's Disease: Evidence from Cellular, Animal, and Human Studies. 2016 , 36, 203-17		59
1141	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. 2016 , 12, 614-22		30
1140	Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?. 2016 , 59, 7389-409		97
1139	An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A β 2 aggregates linked with Alzheimer's disease. 2016 , 2, e1501244		133
1138	Accelerating Medicines Partnership: Alzheimer's Disease (AMP-AD) Knowledge Portal Aids Alzheimer's Drug Discovery through Open Data Sharing. 2016 , 20, 389-91		70
1137	Neuroimaging biomarkers in Alzheimer's disease and other dementias. 2016 , 30, 4-16		27
1136	Opportunities and challenges in developing relevant animal models for Alzheimer's disease. 2016 , 26, 112-4		30

1135	No screams and cries will convince us that white is white and black is black—An ode to the defenders of amyloid cascade hypothesis of Alzheimer’s disease. 2016 , 327-328, 35-42	6
1134	Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease. 2016 , 2, 1-12	44
1133	Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease. 2016 , 34, 681-707	11
1132	Can cloud-based tools accelerate Alzheimer’s disease drug discovery?. 2016 , 11, 215-23	17
1131	Open Access Could Transform Drug Discovery: A Case Study of JQ1. 2016 , 11, 321-32	19
1130	Accelerating stem cell trials for Alzheimer’s disease. 2016 , 15, 219-230	57
1129	Human Cortical Neural Stem Cells Expressing Insulin-Like Growth Factor-I: A Novel Cellular Therapy for Alzheimer’s Disease. 2016 , 5, 379-91	43
1128	Knowledge and Attitudes in Alzheimer’s Disease in a Cohort of Older African Americans and Caucasians. 2016 , 31, 361-7	5
1127	MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. 2016 , 37, 26-37	35
1126	Brain-inspired cheminformatics of drug-target brain interactome, synthesis, and assay of TVP1022 derivatives. 2016 , 103, 270-8	48
1125	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of A β amyloid (1-42) in human cerebrospinal fluid. 2016 , 12, 517-26	179
1124	Therapeutic strategies for Alzheimer’s disease in clinical trials. 2016 , 68, 127-38	298
1123	Genome instability in Alzheimer disease. 2017 , 161, 83-94	62
1122	The current and future burden of late-onset dementia in the United Kingdom: Estimates and interventions. 2017 , 13, 38-44	7
1121	Zinc and Copper Differentially Modulate Amyloid Precursor Protein Processing by B β Secretase and Amyloid- β Peptide Production. 2017 , 292, 3751-3767	51
1120	Current issues and future research priorities for health economic modelling across the full continuum of Alzheimer’s disease. 2017 , 13, 312-321	22
1119	Targeting A β amyloid plaques and oligomers: development of near-IR fluorescence imaging probes. 2017 , 9, 179-198	15
1118	Novel multitarget-directed tacrine derivatives as potential candidates for the treatment of Alzheimer’s disease. 2017 , 32, 572-587	42

1117	Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends. 2017 , 37, 1186-1225		176
1116	Preclinical Evaluation of F-JNJ64349311, a Novel PET Tracer for Tau Imaging. 2017 , 58, 975-981		49
1115	Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 10	9	104
1114	Clinically Meaningful Outcomes in Early Alzheimer Disease: A Consortia-Driven Approach to Identifying What Matters to Patients. 2017 , 51, 380-390		6
1113	Biophenols pharmacology against the amyloidogenic activity in Alzheimer's disease. 2017 , 89, 396-413		29
1112	[Preventive strategies for dementia]. 2017 , 50, 89-95		13
1111	Introducing Therioepistemology: the study of how knowledge is gained from animal research. 2017 , 46, 103-113		48
1110	Focused design of polypharmacophoric neuroprotective compounds: Conjugates of β -carbolines with carbazole derivatives and tetrahydrocarbazole. 2017 , 89, 1167-1184		20
1109	Alzheimer's disease, dementia, and stem cell therapy. 2017 , 8, 111		157
1108	Accelerating drug development for Alzheimer's disease through the use of data standards. 2017 , 3, 273-283		7
1107	Targeting neuronal function for CNS drug discovery. 2017 , 23, 17-25		4
1106	Sphingolipid-Enriched Extracellular Vesicles and Alzheimer's Disease: A Decade of Research. 2017 , 60, 757-768		35
1105	Understanding mechanisms and seeking cures for Alzheimer's disease: why we must be "extraordinarily diverse". 2017 , 313, C353-C361		6
1104	Evidence for widespread, severe brain copper deficiency in Alzheimer's dementia. 2017 , 9, 1106-1119		47
1103	Modulating 5-HT and 5-HT receptors in Alzheimer's disease treatment. 2017 , 9, 781-795		24
1102	Neurodegenerative drug discovery: building on the past, looking to the future. 2017 , 9, 707-709		10
1101	A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment. 2017 , 77, 92-105		10
1100	The promise of organ and tissue preservation to transform medicine. 2017 , 35, 530-542		246

1099	Alzheimer's disease drug development pipeline: 2017. 2017 , 3, 367-384	256
1098	Effects of the Insulin Sensitizer Metformin in Alzheimer Disease: Pilot Data From a Randomized Placebo-controlled Crossover Study. 2017 , 31, 107-113	157
1097	Discovery of Potent Dual Binding Site Acetylcholinesterase Inhibitors via Homo- and Heterodimerization of Coumarin-Based Moieties. 2017 , 12, 1349-1358	18
1096	Differentiation of Inflammation-Responsive Astrocytes from Glial Progenitors Generated from Human Induced Pluripotent Stem Cells. 2017 , 8, 1757-1769	79
1095	Dissociable diffusion MRI patterns of white matter microstructure and connectivity in Alzheimer's disease spectrum. 2017 , 7, 45131	28
1094	Novel conjugates of aminoadamantanes with carbazole derivatives as potential multitarget agents for AD treatment. 2017 , 7, 45627	42
1093	Nutrition as a component of dementia risk reduction strategies. 2017 , 30, 40-45	6
1092	2017 Alzheimer's disease facts and figures. 2017 , 13, 325-373	795
1091	The value of PET ligand discovery to CNS drug development. 2017 , 9, 351-356	3
1090	Translatable Models of Brain and Cognitive Reserve. 2017 , 79-104	1
1089	Systematic development of small molecules to inhibit specific microscopic steps of A β 2 aggregation in Alzheimer's disease. 2017 , 114, E200-E208	134
1088	Alzheimer's disease: experimental models and reality. 2017 , 133, 155-175	274
1087	Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer's disease. 2017 , 73, 340-358	20
1086	Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease. 2017 , 140, 561-575	66
1085	Neuroprotective Effect of SLM, a Novel Carbazole-Based Fluorophore, on SH-SY5Y Cell Model and 3xTg-AD Mouse Model of Alzheimer's Disease. 2017 , 8, 676-685	13
1084	Pharmacological Rescue of Long-Term Potentiation in Alzheimer Diseased Synapses. 2017 , 37, 1197-1212	39
1083	Human umbilical cord mesenchymal stem cells transplantation improves cognitive function in Alzheimer's disease mice by decreasing oxidative stress and promoting hippocampal neurogenesis. 2017 , 320, 291-301	74
1082	Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease. 2017 , 3, 1-9	9

1081	Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice. 2017 , 73, 297-305	2
1080	The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review. 2017 , 815, 364-375	79
1079	Identification of a Novel 1,2,3,4-Tetrahydrobenzo[b][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease. 2017 , 60, 8858-8875	32
1078	Identification of key regions and residues controlling A β folding and assembly. 2017 , 7, 12434	16
1077	The role of the immune system in Alzheimer disease: Etiology and treatment. 2017 , 40, 84-94	86
1076	WITHDRAWN: Revisiting the cholinergic hypothesis in Alzheimer's disease: Emerging evidence from translational and clinical research. 2017 ,	13
1075	Conditional Deletion of Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease. 2017 , 37, 9207-9221	29
1074	Preventive Effect of Rifampicin on Alzheimer Disease Needs at Least 450 mg Daily for 1 Year: An FDG-PET Follow-Up Study. 2017 , 7, 204-214	15
1073	Genetics of Alzheimer's disease: From pathogenesis to clinical usage. 2017 , 45, 1-8	24
1072	Resolving the Atomistic Modes of Anle138b Inhibitory Action on Peptide Oligomer Formation. 2017 , 8, 2791-2808	19
1071	Therapeutic Approaches to Prion Diseases. 2017 , 150, 433-453	6
1070	Novel Vilazodone-Tacrine Hybrids as Potential Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease Accompanied with Depression: Design, Synthesis, and Biological Evaluation. 2017 , 8, 2708-2721	26
1069	Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease. 2017 , 139, 378-389	15
1068	Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?. 2017 , 3, 402-409	65
1067	Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease. 2017 , 7, 6763	41
1066	Advancing Alzheimer's research: A review of big data promises. 2017 , 106, 48-56	32
1065	Replicable Expansion and Differentiation of Neural Precursors from Adult Canine Skin. 2017 , 9, 557-570	3
1064	Multiple Ligands in Neurodegenerative Diseases. 2017 , 477-508	1

1063	Alzheimer's Disease: Past, Present, and Future. 2017 , 23, 818-831	219
1062	Why do so many clinical trials of therapies for Alzheimer's disease fail?. 2017 , 390, 2327-2329	111
1061	Tangled tau: Active pathology or footprint of disease?. 2017 , 3, 658-659	
1060	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. 2017 , 6, 157-163	39
1059	Drug discovery and development: Role of basic biological research. 2017 , 3, 651-657	178
1058	Alzheimer's Disease-Current Status and Future Directions. 2017 , 20, 1141-1151	13
1057	Montessori education: a review of the evidence base. 2017 , 2, 11	34
1056	Recent Progress in the Pharmacotherapy of Alzheimer's Disease. 2017 , 34, 811-820	31
1055	Implications of peptide assemblies in amyloid diseases. 2017 , 46, 6492-6531	198
1054	Advances in Alzheimer's Diagnosis and Therapy: The Implications of Nanotechnology. 2017 , 35, 937-953	87
1053	The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease. 2017 , 30, 136-144	21
1052	Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging. 2017 , 56, 75-88	22
1051	Pittsburgh Compound-B (PiB) binds amyloid β protein protofibrils. 2017 , 140, 210-215	21
1050	Cognitive 'Omics': Pattern-Based Validation of Potential Drug Targets. 2017 , 38, 113-126	10
1049	Visual system manifestations of Alzheimer's disease. 2017 , 95, e668-e676	29
1048	A First-in-Class Small-Molecule that Acts as a Dual Inhibitor of HDAC and PDE5 and that Rescues Hippocampal Synaptic Impairment in Alzheimer's Disease Mice. 2017 , 42, 524-539	65
1047	TLR4 is a link between diabetes and Alzheimer's disease. 2017 , 316, 234-244	67
1046	Nutrition for the ageing brain: Towards evidence for an optimal diet. 2017 , 35, 222-240	120

1045	A novel 384-multiwell microelectrode array for the impedimetric monitoring of Tau protein induced neurodegenerative processes. 2017 , 88, 78-84	16
1044	Design, synthesis, in-silico and biological evaluation of novel donepezil derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease. 2017 , 125, 736-750	65
1043	Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin. 2018 , 61, 321-332	13
1042	Is iron associated with amyloid involved in the oxidative stress of Alzheimer's disease?. 2017 , 20, 987-989	6
1041	Failure to Recover from Proactive Semantic Interference and Abnormal Limbic Connectivity in Asymptomatic, Middle-Aged Offspring of Patients with Late-Onset Alzheimer's Disease. 2017 , 60, 1183-1193	23
1040	Medicinal Chemistry of Hybrids for Neurodegenerative Diseases. 2017 , 259-277	3
1039	Analytical Strategy to Prioritize Alzheimer's Disease Candidate Genes in Gene Regulatory Networks Using Public Expression Data. 2017 , 59, 1237-1254	12
1038	Exploratory trials in mental health: anything to learn from other disciplines?. 2017 , 20, 21-24	2
1037	Therapie der Alzheimer-Demenz [Was kommt?. 2017 , 19, 36-44	
1036	Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer's Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches. 2017 , 22,	14
1035	Rodent Models for Alzheimer's Disease in Drug Discovery. 2017 , 235-247	3
1034	Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition. 2017 , 8,	63
1033	A New Noncanonical Anionic Peptide That Translocates a Cellular Blood-Brain Barrier Model. 2017 , 22,	17
1032	Multitarget Anti-Alzheimer Hybrid Compounds. 2017 , 167-192	6
1031	Physical Activity: A Viable Way to Reduce the Risks of Mild Cognitive Impairment, Alzheimer's Disease, and Vascular Dementia in Older Adults. 2017 , 7,	69
1030	Nature Versus Nurture: Does Proteostasis Imbalance Underlie the Genetic, Environmental, and Age-Related Risk Factors for Alzheimer's Disease?. 2017 , 5,	2
1029	Relationship between Cognitive and Sleep-wake Variables in Asymptomatic Offspring of Patients with Late-onset Alzheimer's Disease. 2017 , 9, 93	10
1028	Anodal Transcranial Direct Current Stimulation Promotes Frontal Compensatory Mechanisms in Healthy Elderly Subjects. 2017 , 9, 420	25

1027	Analysis of Amyloid-Pathology Spread in Mouse Models Suggests Spread Is Driven by Spatial Proximity, Not Connectivity. 2017 , 8, 653	15
1026	Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders. 2017 , 11, 451	84
1025	Antidiabetic Drugs in Alzheimer's Disease: Mechanisms of Action and Future Perspectives. 2017 , 2017, 7420796	28
1024	Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Clinical Evidence and Possible Mechanisms. 2017 , 2017, 9416305	23
1023	The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. 2017 , 7,	21
1022	Mixed pathologies and neural reserve: Implications of complexity for Alzheimer disease drug discovery. 2017 , 14, e1002256	33
1021	Drug candidates in clinical trials for Alzheimer's disease. 2017 , 24, 47	226
1020	Old and new inflammation and infection hypotheses of Alzheimer's disease: focus on Microglia-aging for chronic neuroinflammation. 2017 , 150, 141-147	2
1019	Modifiable pathways in Alzheimer's disease: Mendelian randomisation analysis. 2017 , 359, j5375	139
1018	Peripheral Inflammatory Biomarkers and Cognitive Decline in Older Adults With and Without Alzheimer's Disease: A Systematic Review. 2017 , 43, 53-60	7
1017	Towards the virtual human patient. Quantitative Systems Pharmacology in Alzheimer's disease. 2017 , 817, 38-45	6
1016	Metabolism-Centric Overview of the Pathogenesis of Alzheimer's Disease. 2017 , 58, 479-488	61
1015	When Patient Engagement and Research Ethics Collide: Lessons from a Dementia Forum. 2017 , 59, 1-10	27
1014	From Imaging Agents to Theranostic Drugs in Alzheimer's Disease. 2017 , 74-106	
1013	Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System. 2018 , 57, 1059-1074	17
1012	Stimulus package. 2018 , 24, 247	12
1011	Alkynyl and Eketophosphonates: Selective and potent butyrylcholinesterase inhibitors. 2018 , 77, 420-428	11
1010	Interventional programmes to improve cognition during healthy and pathological ageing: Cortical modulations and evidence for brain plasticity. 2018 , 43, 81-98	44

1009	Past to Future: What Animal Models Have Taught Us About Alzheimer's Disease. 2018 , 64, S365-S378	12
1008	Neurobiological findings associated with high cognitive performance in older adults: a systematic review. 2018 , 30, 1813-1825	8
1007	Development of coumarin-benzofuran hybrids as versatile multitargeted compounds for the treatment of Alzheimer's Disease. 2018 , 92, 1497-1503	14
1006	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. 2018 , 64, S3-S22	74
1005	Stromal cell-laden 3D hydrogel microwell arrays as tumor microenvironment model for studying stiffness dependent stromal cell-cancer interactions. 2018 , 170, 37-48	52
1004	Protein and Peptides for Elderly Health. 2018 , 112, 265-308	6
1003	Precision pharmacology for Alzheimer's disease. 2018 , 130, 331-365	60
1002	Human iPS-Derived Astroglia from a Stable Neural Precursor State Show Improved Functionality Compared with Conventional Astrocytic Models. 2018 , 10, 1030-1045	50
1001	AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. 2018 , 29, 24-47	52
1000	Regulatory-accepted drug development tools are needed to accelerate innovative CNS disease treatments. 2018 , 151, 291-306	20
999	Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ-Fibrinogen Interaction and Aβ-Induced Contact System Activation. 2018 , 57, 1399-1409	9
998	Novel Tacrine-Hydroxyphenylbenzimidazole hybrids as potential multitarget drug candidates for Alzheimer's disease. 2018 , 148, 255-267	47
997	Health Policy and Dementia. 2018 , 20, 4	5
996	Characterization of a 3xTg-AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background. 2018 , 72, e22025	9
995	Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models. 2018 , 136, 251-259	86
994	Preparation of Tetradentate Copper Chelators as Potential Anti-Alzheimer Agents. 2018 , 13, 684-704	27
993	Automation on an Open-Access Platform of Alzheimer's Disease Biomarker Immunoassays. 2018 , 23, 188-197	3
992	A biosensor-based framework to measure latent proteostasis capacity. 2018 , 9, 287	25

991	Identification of a Novel Positron Emission Tomography (PET) Ligand for Imaging β Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE-1) in Brain. 2018 , 61, 3296-3308		13
990	Florbetapir-PET β myloid imaging and associated neuropsychological trajectories in survivors of critical illness: A case series. 2018 , 44, 331-336		6
989	Drug discovery, development and delivery in Alzheimer's disease. 2017 , 35, 3		5
988	The Pivotal Role of Copper in Neurodegeneration: A New Strategy for the Therapy of Neurodegenerative Disorders. 2018 , 15, 808-820		49
987	Acetylshikonin from Zicao attenuates cognitive impairment and hippocampus senescence in d-galactose-induced aging mouse model via upregulating the expression of SIRT1. 2018 , 137, 311-318		30
986	The mitochondrial ATP synthase is a shared drug target for aging and dementia. 2018 , 17, e12715		70
985	Principles of designing a clinical trial: optimizing chances of trial success. 2018 , 5, 143-152		1
984	Alzheimer's disease drug development pipeline: 2018. 2018 , 4, 195-214		359
983	Health economic evaluations of non-pharmacological interventions for persons with dementia and their informal caregivers: a systematic review. 2018 , 18, 69		23
982	Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 4	9	20
981	A self-destructive nanosweeper that captures and clears amyloid β peptides. 2018 , 9, 1802		96
980	Prions, prionoids and protein misfolding disorders. 2018 , 19, 405-418		138
979	Potential Novel Approaches to Understand the Pathogenesis and Treat Alzheimer's Disease. 2018 , 64, S299-S312		18
978	2018 Alzheimer's disease facts and figures. 2018 , 14, 367-429		1154
977	Acetophenone derivatives from the root bark of <i>Cynanchum wilfordii</i> as potential neuroprotective agents. 2018 , 24, 179-183		2
976	Anti- β drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease. 2018 , 143, 2204-2212		16
975	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. 2018 , 64, S47-S105		84
974	Pleiotropy and promiscuity in pharmacogenomics for the treatment of Alzheimer's disease and related risk factors. 2018 , 13, 71-86		13

973	Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. 2018 , 64, S405-S426	36
972	Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer's disease: A focus on human studies. 2018 , 131, 32-43	96
971	Calcium signaling and molecular mechanisms underlying neurodegenerative diseases. 2018 , 70, 87-94	151
970	Temporal association patterns and dynamics of amyloid- β and tau in Alzheimer's disease. 2018 , 33, 657-666	15
969	Are rodent models of Parkinson's disease behaving as they should?. 2018 , 352, 133-141	34
968	Recent Advances in Computational Approaches for Designing Potential Anti-Alzheimer's Agents. 2018 , 25-59	2
967	Molecular Docking and Molecular Dynamics Simulation to Evaluate Compounds That Avoid the Amyloid Beta 1-42 Aggregation. 2018 , 229-248	4
966	Therapeutic peptides for CNS indications: Progress and challenges. 2018 , 26, 2859-2862	13
965	Multimedia Aided Consent for Alzheimer's Disease Research. 2018 , 41, 20-32	15
964	The wonderland of neuronal nicotinic acetylcholine receptors. 2018 , 151, 214-225	73
963	Amylin in Alzheimer's disease: Pathological peptide or potential treatment?. 2018 , 136, 287-297	13
962	Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model. 2018 , 130, 54-61	27
961	(-)-P7C3-S243 Protects a Rat Model of Alzheimer's Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia. 2018 , 84, 488-498	39
960	Revalidation of the neuroprotective effects of a United States patented polyherbal formulation on scopolamine induced learning and memory impairment in rats. 2018 , 97, 1046-1052	14
959	Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. 2018 , 11, 147-152	149
958	Technological Peer Pressure and Product Disclosure. 2018 , 93, 95-126	29
957	Introduction: A Framework for Understanding Impacts of Dementia and Supporting Quality of Life With Disease Progression. 2018 , xxix-l	
956	A strategy to find novel candidate anti-Alzheimer's disease drugs by constructing interaction networks between drug targets and natural compounds in medical plants. 2018 , 6, e4756	5

955	Protein production is an early biomarker for RNA-targeted therapies. 2018 , 5, 1492-1504	3
954	The genes associated with early-onset Alzheimer's disease. 2018 , 9, 15132-15143	41
953	Using Human Pluripotent Stem Cell-Derived Neural Cultures to Assess Safety of New Drugs and Chemicals. 2018 ,	
952	Brain Theranostics and Radiotheranostics: Exosomes and Graphenes In Vivo as Novel Brain Theranostics. 2018 , 52, 407-419	4
951	Cholinergic Mechanisms of Target Oddball Stimuli Detection: The Late "P300-Like" Event-Related Potential in Rats. 2018 , 2018, 4270263	7
950	Operationalized definition of older adults with high cognitive performance. 2018 , 12, 221-227	12
949	Be open about drug failures to speed up research. 2018 , 563, 317-319	24
948	Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease. 2018 , 9, 6128-6143	67
947	Dihydroquinoline Carbamate DQS1-02 as a Prodrug of a Potent Acetylcholinesterase Inhibitor for Alzheimer's Disease Therapy: Multigram-Scale Synthesis, Mechanism Investigations, in Vitro Safety Pharmacology, and Preliminary in Vivo Toxicology Profile. 2018 , 3, 18387-18397	4
946	Effects of Six-Month Aerobic Exercise Intervention on Sleep in Healthy Older Adults in the Study: A Pilot Study. 2018 , 2, 229-238	4
945	Discovery and Chemical Development of JNJ-50138803, a Clinical Candidate BACE1 Inhibitor. 2018 , 91-114	
944	Alzheimer's disease: The right drug, the right time. 2018 , 362, 1250-1251	80
943	The Potential Use of Plant Natural Products and Plant Extracts with Antioxidant Properties for the Prevention/Treatment of Neurodegenerative Diseases: In Vitro, In Vivo and Clinical Trials. 2018 , 23,	115
942	Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. 2018 , 16, 304	114
941	Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer's disease clinical program. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 116	9 11
940	Preparation of 4-Flexible Amino-2-Arylethenyl-Quinoline Derivatives as Multi-target Agents for the Treatment of Alzheimer's Disease. 2018 , 23,	7
939	When Neuroscience Meets Pharmacology: A Neuropharmacology Literature Analysis. 2018 , 12, 852	13
938	Traditional Japanese Herbal Medicine Yokukansan Targets Distinct but Overlapping Mechanisms in Aged Mice and in the 5xFAD Mouse Model of Alzheimer's Disease. 2018 , 10, 411	9

937	Class-Specific Incidence of All-Cause Dementia and Alzheimer's Disease: A Latent Class Approach. 2018 , 66, 347-357	11
936	Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition. 2018 , 66, 11-23	9
935	Future of Aging Research. 2018 , 231-241	2
934	Exploring the chelating capacity of 2-hydroxyphenyl-benzimidazole based hybrids with multi-target ability as anti-Alzheimer's agents. 2018 , 42, 16503-16515	13
933	Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model. 2018 , 17, 2321-2334	5
932	Continual Trials Spontaneous Recognition Tasks in Mice: Reducing Animal Numbers and Improving Our Understanding of the Mechanisms Underlying Memory. 2018 , 12, 214	6
931	Human neural stem cell transplantation improves cognition in a murine model of Alzheimer's disease. 2018 , 8, 14776	47
930	Research Models of Neurodegenerative Diseases: Major Considerations for Translatability. 2018 , 99-101	
929	The Molecular and Neuropathological Consequences of Genetic Risk for Alzheimer's Dementia. 2018 , 12, 699	31
928	The antimicrobial protection hypothesis of Alzheimer's disease. 2018 , 14, 1602-1614	192
927	Cortical thickness, brain metabolic activity, and in vivo amyloid deposition in asymptomatic, middle-aged offspring of patients with late-onset Alzheimer's disease. 2018 , 107, 11-18	10
926	Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. 2019 , 6, 2-15	61
925	The Potential of CRISPR/Cas9 Gene Editing as a Treatment Strategy for Alzheimer's Disease. 2018 , 8,	18
924	Effect of passive finger exercises on grip strength and the ability to perform activities of daily living for older people with dementia: a 12-week randomized controlled trial. 2018 , 13, 2169-2177	8
923	Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?. 2019 , 6, 20-26	
922	Questions concerning the role of amyloid- β in the definition, aetiology and diagnosis of Alzheimer's disease. 2018 , 136, 663-689	101
921	Re-thinking Alzheimer's disease therapeutic targets using gene-based tests. 2018 , 37, 461-470	18
920	Alzheimer's Biomarkers From Multiple Modalities Selectively Discriminate Clinical Status: Relative Importance of Salivary Metabolomics Panels, Genetic, Lifestyle, Cognitive, Functional Health and Demographic Risk Markers. 2018 , 10, 296	14

919	Call of Duty at the Frontier of Research: Normative Epistemology for High-Risk/High-Gain Studies of Deep Brain Stimulation. 2018 , 27, 647-659	
918	Assessment of Cognitive Impairment in a Mouse Model of High-Fat Diet-Induced Metabolic Stress with Touchscreen-Based Automated Battery System. 2018 , 27, 277-286	11
917	Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects. 2018 , 83, 1057-1067	15
916	Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO. 2018 , 17, 1536012118792317	107
915	Acid-base fractions separated from <i>Streblus asper</i> leaf ethanolic extract exhibited antibacterial, antioxidant, anti-acetylcholinesterase, and neuroprotective activities. 2018 , 18, 223	10
914	Metabolomics Analyses of Saliva Detect Novel Biomarkers of Alzheimer's Disease. 2018 , 65, 1401-1416	35
913	Apolipoprotein E region molecular signatures of Alzheimer's disease. 2018 , 17, e12779	20
912	A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer's disease. 2018 , 21, 811-819	220
911	Photopharmacology in Alzheimer's Disease. 2018 , 1, 1800037	6
910	Recommendations toward a human pathway-based approach to disease research. 2018 , 23, 1824-1832	18
909	Quantitative systems pharmacology in model-informed drug development and therapeutic use. 2018 , 10, 19-25	2
908	The price of progress: Funding and financing Alzheimer's disease drug development. 2018 , 4, 330-343	33
907	Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer's Disease Risk Reduction and Early Intervention. 2018 , 38, 6665-6681	81
906	Amyloid clearance defect in ApoE4 astrocytes is reversed by epigenetic correction of endosomal pH. 2018 , 115, E6640-E6649	71
905	Mechanisms of protein toxicity in neurodegenerative diseases. 2018 , 75, 3159-3180	69
904	Biomarkers for Alzheimer's disease: from pathogenesis to drug development. 2018 , 268, 441-442	1
903	Animal-assisted therapy in adults: A systematic review. 2018 , 32, 169-180	32
902	Design, synthesis, X-ray studies, and biological evaluation of novel BACE1 inhibitors with bicyclic isoxazoline carboxamides as the P3 ligand. 2018 , 28, 2605-2610	2

901	Neurohealth Properties of Mycelia Enriched with Erinacines. 2018 , 2018, 5802634	32
900	Genetic Risk for Age-Related Cognitive Impairment Does Not Predict Cognitive Performance in Middle Age. 2018 , 64, 459-471	6
899	Tau-Centric Multitarget Approach for Alzheimer's Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3 and Tau-Aggregation Inhibitors. 2018 , 61, 7640-7656	53
898	Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers. 2018 , 15, 164-181	31
897	Ocular Manifestations of Alzheimer's and Other Neurodegenerative Diseases: The Prospect of the Eye as a Tool for the Early Diagnosis of Alzheimer's Disease. 2018 , 2018, 8538573	41
896	Ethanol Extract of <i>Opuntia ficus-indica</i> var. <i>saboten</i> Ameliorates Cognitive Dysfunction Induced by Cholinergic Blockade in Mice. 2018 , 21, 971-978	2
895	White Matter and Cognition in Traumatic Brain Injury. 2018 , 65, 345-362	20
894	Multi-omic Directed Networks Describe Features of Gene Regulation in Aged Brains and Expand the Set of Genes Driving Cognitive Decline. 2018 , 9, 294	14
893	The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. 2018 , 5, 108	40
892	Mechanisms of Risk Reduction in the Clinical Practice of Alzheimer's Disease Prevention. 2018 , 10, 96	19
891	Application of Metabolomics in Alzheimer's Disease. 2017 , 8, 719	117
890	Challenges for Alzheimer's Disease Therapy: Insights from Novel Mechanisms Beyond Memory Defects. 2018 , 12, 37	77
889	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. 2018 , 12, 254	11
888	2D versus 3D human induced pluripotent stem cell-derived cultures for neurodegenerative disease modelling. 2018 , 13, 27	105
887	A Systematic Review of Anti-amyloidogenic and Metal-Chelating Peptoids: Two Structural Motifs for the Treatment of Alzheimer's Disease. 2018 , 23,	11
886	Cognitive training for people with mild to moderate dementia. 2018 ,	5
885	Spontaneous development of Alzheimer's disease-associated brain pathology in a Shugoshin-1 mouse cohesinopathy model. 2018 , 17, e12797	13
884	Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?. 2018 , 64, 981-993	8

883	Use of quantitative clinical pharmacology to improve early clinical development success in neurodegenerative diseases. 2018 , 11, 789-795		8
882	Anti-βsheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer's disease model. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 10	9	14
881	Early brain connectivity alterations and cognitive impairment in a rat model of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018 , 10, 16	9	30
880	Benzofuran and Indole: Promising Scaffolds for Drug Development in Alzheimer's Disease. 2018 , 13, 1275-1299		79
879	An arabinogalactan from fruits of <i>Lycium barbarum</i> L. inhibits production and aggregation of Aβ 2018 , 195, 643-651		26
878	Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild Cognitive Impairment due to Alzheimer's disease. 2018 , 8, 7490		54
877	Tacrine-deferiprone hybrids as multi-target-directed metal chelators against Alzheimer's disease: a two-in-one drug. 2018 , 10, 1460-1475		22
876	Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases - Pages 109-136. 2018 , 109-136		
875	Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice. 2018 , 15, 182		6
874	Go with the Flow-Microfluidics Approaches for Amyloid Research. 2018 , 13, 3437-3447		8
873	Phenylpropanoids and Alzheimer's disease: A potential therapeutic platform. 2018 , 120, 99-111		19
872	Three Decades of Dementia Research: Insights from One Small Community of Indomitable Rotterdammers. 2018 , 64, S145-S159		1
871	The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade. 2018 , 64, S567-S610		339
870	Effects of mesenchymal stem cells transplantation on cognitive deficits in animal models of Alzheimer's disease: A systematic review and meta-analysis. 2018 , 8, e00982		12
869	Beneficial Effects of <i>Sideritis scardica</i> and <i>Cichorium spinosum</i> against Amyloidogenic Pathway and Tau Misprocessing in Alzheimer's Disease Neuronal Cell Culture Models. 2018 , 64, 787-800		3
868	The development of a stochastic mathematical model of Alzheimer's disease to help improve the design of clinical trials of potential treatments. 2018 , 13, e0190615		16
867	Development and validation of a novel dementia of Alzheimer's type (DAT) score based on metabolism FDG-PET imaging. 2018 , 18, 802-813		22
866	Religious Orders Study and Rush Memory and Aging Project. 2018 , 64, S161-S189		304

865	Does Treating Vascular Risk Factors Prevent Dementia and Alzheimer's Disease? A Systematic Review and Meta-Analysis. 2018 , 64, 657-668	45
864	Human-specific approaches to brain research for the 21st century: a South American perspective. 2018 , 23, 1929-1935	1
863	Biomedical informatics applications for precision management of neurodegenerative diseases. 2018 , 4, 357-365	3
862	Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders. 2018 , 22, 615-628	12
861	Treatment of Alzheimer's Disease. 2018 , 119-126	
860	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. 2019 , 29, 63-74	27
859	A call for a global 'bigger' data approach to Alzheimer disease. 2019 , 18, 319-320	5
858	Rational Design of Novel Selective Dual-Target Inhibitors of Acetylcholinesterase and Monoamine Oxidase B as Potential Anti-Alzheimer's Disease Agents. 2019 , 10, 482-496	19
857	Novel multi target-directed ligands targeting 5-HT receptors with in cellulo antioxidant properties as promising leads in Alzheimer's disease. 2019 , 182, 111596	8
856	Multifunctional Mono-Triazole Derivatives Inhibit A β Aggregation and Cu-Mediated A β Aggregation and Protect Against A β Induced Cytotoxicity. 2019 , 32, 1824-1839	16
855	A Therapeutic Strategy for Alzheimer's Disease Focused on Immune-inflammatory Modulation. 2019 , 18, 33-46	20
854	Variation across Species and Levels: Implications for Model Species Research. 2019 , 93, 57-69	10
853	Spatial distributions of cholinergic impairment and neuronal hypometabolism differ in MCI due to AD. 2019 , 24, 101978	8
852	Making DEEP Sense of Lifestyle Risk and Resilience. 2019 , 11, 171	2
851	Protein-Capped Metal Nanoparticles Inhibit Tau Aggregation in Alzheimer's Disease. 2019 , 4, 12833-12840	52
850	Electro-acupuncture therapy to improve spatial learning and memory in APP ^{swe} /PS1 ^{dE9} transgenic mice through the inhibition of the TLR4/MyD88 signaling pathway. 2019 , 6, 184-192	0
849	A novel class of multitarget anti-Alzheimer benzohomoadamantane-chlorotacrine hybrids modulating cholinesterases and glutamate NMDA receptors. 2019 , 180, 613-626	17
848	Molecular modeling of cardanol-derived AChE inhibitors. 2019 , 731, 136591	3

847	Early Electrophysiological Disintegration of Hippocampal Neural Networks in a Novel Locus Coeruleus Tau-Seeding Mouse Model of Alzheimer's Disease. 2019 , 2019, 6981268	11
846	Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer's Disease. 2019 , 11, 149	21
845	Are some animal models more equal than others? A case study on the translational value of animal models of efficacy for Alzheimer's disease. 2019 , 859, 172524	16
844	Tackling gaps in developing life-changing treatments for dementia. 2019 , 5, 241-253	11
843	Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. 2019 , 6, 157-163	39
842	Anti-Alzheimer's Disease Activity of Bromophenols from a Red Alga, (Harvey) Yamada. 2019 , 4, 12259-12270	16
841	110 Anniversary: Nanoparticle mediated drug delivery for the treatment of Alzheimer's disease: Crossing the blood-brain barrier. 2019 , 58, 15079-15087	14
840	Rubrofusarin inhibits A β aggregation and ameliorates memory loss in an A β induced Alzheimer's disease-like mouse model. 2019 , 132, 110698	5
839	A Snapshot on the Current Status of Alzheimer's Disease, Treatment Perspectives, in-Vitro and in-Vivo Research Studies and Future Opportunities. 2019 , 67, 1030-1041	4
838	Neuronal Circuit-Based Computer Modeling as a Phenotypic Strategy for CNS R&D. 2019 , 13, 723	2
837	Acoustic enhancement of sleep slow oscillations in mild cognitive impairment. 2019 , 6, 1191-1201	33
836	The Use of Pigs as a Translational Model for Studying Neurodegenerative Diseases. 2019 , 10, 838	14
835	Red Ginseng Attenuates A β Induced Mitochondrial Dysfunction and A β Mediated Pathology in an Animal Model of Alzheimer's Disease. 2019 , 20,	22
834	Cerebral Vitamin B5 (D-Pantothenic Acid) Deficiency as a Potential Cause of Metabolic Perturbation and Neurodegeneration in Huntington's Disease. 2019 , 9,	26
833	Biomarker-Guided Drug Development for Better Defined Early Patient Studies and Clinical Trial Efficiency. 2019 , 17-23	0
832	Regulatory Science Objectives and Biomarker Qualification Through Public-Private Partnerships Are Critical to Delivering Innovative Treatments for CNS Diseases. 2019 , 29, 277-296	
831	Translational Medicine Strategies in Alzheimer's Disease Drug Development. 2019 , 349-362	
830	Enhanced Molecular Appreciation of Psychiatric Disorders Through High-Dimensionality Data Acquisition and Analytics. 2019 , 2011, 671-723	8

829	Metal Ions in Alzheimer's Disease: A Key Role or Not?. 2019 , 52, 2026-2035	117
828	CDEK: Clinical Drug Experience Knowledgebase. 2019 , 2019,	6
827	AARP:. 2019 , 17, 415-419	
826	Clinical Characteristics in Subjective Cognitive Decline with and without Worry: Baseline Investigation of the SILCODE Study. 2019 , 72, 443-454	13
825	Pharmaceutical crisis. 2019 , 1-10	
824	Forecasting the progression of Alzheimer's disease using neural networks and a novel preprocessing algorithm. 2019 , 5, 483-491	29
823	Future horizons in Alzheimer's disease research. 2019 , 168, 223-241	10
822	Treatment of Neurodegeneration: Integrating Photobiomodulation and Neurofeedback in Alzheimer's Dementia and Parkinson's: A Review. 2019 , 37, 623-634	11
821	Using Machine Learning to Classify Bioactivity for 3486 Per- and Polyfluoroalkyl Substances (PFASs) from the OECD List. 2019 , 53, 13970-13980	29
820	Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease. 2019 , 72, 931-946	13
819	Temporal changes in cardiorespiratory fitness and risk of dementia incidence and mortality: a population-based prospective cohort study. 2019 , 4, e565-e574	28
818	Non-pharmacological therapeutic strategy options for patients with dementia based on cognitive function-A Bayesian network meta-analysis of randomized controlled trials. 2019 , 56, 100965	1
817	Use of Mendelian Randomization to Examine Causal Inference in Osteoporosis. 2019 , 10, 807	10
816	Circularity, psychiatry & biomarkers: The operationalisation of Alzheimer's & stress in research. 2019 , 239, 112553	6
815	Xestospongins C, a Reversible IP3 Receptor Antagonist, Alleviates the Cognitive and Pathological Impairments in APP/PS1 Mice of Alzheimer's Disease. 2019 , 72, 1217-1231	10
814	A Human Embryonic Stem Cell Model of A β -Dependent Chronic Progressive Neurodegeneration. 2019 , 13, 1007	2
813	Why Is Tetradentate Coordination Essential for Potential Copper Homeostasis Regulators in Alzheimer's Disease?. 2019 , 2019, 4712-4718	9
812	Dietary Neuroketotherapeutics for Alzheimer's Disease: An Evidence Update and the Potential Role for Diet Quality. 2019 , 11,	21

811	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects. 2019 , 71, 581-595	9
810	Is Combining an Anticholinergic with a Cholinesterase Inhibitor a Good Strategy for High-Level CNS Cholinesterase Inhibition?. 2019 , 71, 1099-1103	1
809	Dementia 2. Alzheimer's disease: diagnosis, treatment and management. 2019 , 13, 329-335	2
808	Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. 2019 , 71, 715-732	58
807	Quercetin Encapsulated Polymer Nanoparticle for Inhibiting Intracellular Polyglutamine Aggregation.. 2019 , 2, 5298-5305	15
806	Early Stage Glycosylation Biomarkers in Alzheimer's Disease. 2019 , 6,	18
805	Network-guided analysis of hippocampal proteome identifies novel proteins that colocalize with A β in a mice model of early-stage Alzheimer's disease. 2019 , 132, 104603	5
804	The "rights" of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 76	9 93
803	Face-to-Face and Digital Multidomain Lifestyle Interventions to Enhance Cognitive Reserve and Reduce Risk of Alzheimer's Disease and Related Dementias: A Review of Completed and Prospective Studies. 2019 , 11,	16
802	Developing Trojan horses to induce, diagnose and suppress Alzheimer's pathology. 2019 , 149, 104471	6
801	CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer's disease. 2019 , 14, e0222757	3
800	Discovering highly selective and diverse PPAR-delta agonists by ligand based machine learning and structural modeling. 2019 , 9, 1106	16
799	Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier. 2019 , 20,	70
798	Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. 2019 , 67, 779-794	163
797	Nutrients in Alzheimer's Disease: The Interaction of Diet, Drugs and Disease. 2019 , 46, 23-34	3
796	The effects of pinoresinol on cholinergic dysfunction-induced memory impairments and synaptic plasticity in mice. 2019 , 125, 376-382	6
795	Blood-brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice. 2019 , 294, 2606-2615	6
794	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. 2019 , 27, 823-834	85

793	State of the science on mild cognitive impairment (MCI). 2019 , 24, 78-87	52
792	Evaluation of urinary 8-hydroxy-2-deoxyguanosine level in experimental Alzheimer's disease: Impact of carvacrol nanoparticles. 2019 , 46, 4517-4527	15
791	Identification of novel small molecules against GSK3 β for Alzheimer's disease using chemoinformatics approach. 2019 , 91, 91-104	17
790	Synthesis and characterization of 8-aminoquinolines, substituted by electron donating groups, as high-affinity copper chelators for the treatment of Alzheimer's disease. 2019 , 22, 419-427	1
789	Magnetoencephalography applied to the study of Alzheimer's disease. 2019 , 165, 25-61	7
788	Development of the "hidden" multifunctional agents for Alzheimer's disease. 2019 , 177, 247-258	13
787	Specific keratinase derived designer peptides potently inhibit A aggregation resulting in reduced neuronal toxicity and apoptosis. 2019 , 476, 1817-1841	4
786	Transcriptional Dysregulation Study Reveals a Core Network Involving the Progression of Alzheimer's Disease. 2019 , 11, 101	10
785	Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease. 2019 , 5, 164-174	9
784	Preventive approach for overcoming dementia. 2019 , 42, 647-657	6
783	Navigating the disease landscape: knowledge representations for contextualizing molecular signatures. 2019 , 20, 609-623	12
782	Unifying Hypothesis of Dopamine Neuron Loss in Neurodegenerative Diseases: Focusing on Alzheimer's Disease. 2019 , 12, 123	26
781	Combining hippocampal volume metrics to better understand Alzheimer's disease progression in at-risk individuals. 2019 , 9, 7499	9
780	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. 2019 , 15, 817-827	26
779	In Vivo Synaptic Density Imaging with C-UCB-J Detects Treatment Effects of Saracatinib in a Mouse Model of Alzheimer Disease. 2019 , 60, 1780-1786	33
778	Assessing drug response in engineered brain microenvironments. 2019 , 150, 21-34	5
777	Prevention and Treatment of Alzheimer's Disease: Biological Mechanisms of Exercise. 2019 , 69, 311-338	24
776	Rational design, cognition and neuropathology evaluation of QTC-4-MeOBnE in a streptozotocin-induced mouse model of sporadic Alzheimer's disease. 2019 , 9, 7276	15

775	Animal Models of Alzheimer's Disease. 2019 , 291-310	0
774	Multi-targeted ChEI-copper chelating molecules as neuroprotective agents. 2019 , 174, 216-225	10
773	Impaired Reversal Learning in APPPS1-21 Mice in the Touchscreen Visual Discrimination Task. 2019 , 13, 92	10
772	Disease Modification in Alzheimer's Disease: Current Thinking. 2019 , 216847901984189	1
771	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). 2019 , 20, 191	57
770	BACE-1 and β -Secretase as Therapeutic Targets for Alzheimer's Disease. 2019 , 12,	49
769	Nanoparticles for drug delivery targeting neurodegeneration in brain and eye. 2019 , 149-183	1
768	The NAAG'ing Concerns of Modeling Human Alzheimer's Disease in Mice. 2019 , 68, 939-945	2
767	LY379268 Does Not Have Long-Term Procognitive Effects nor Attenuate Glutamatergic Signaling in APP/PS1 Mice. 2019 , 68, 1193-1209	5
766	Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. 2019 , 101, 1003-1015	18
765	New Multitarget Hybrids Bearing Tacrine and Phenylbenzothiazole Motifs as Potential Drug Candidates for Alzheimer's Disease. 2019 , 24,	8
764	Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease. 2019 , 2019, 6216530	14
763	Astrocyte senescence: Evidence and significance. 2019 , 18, e12937	83
762	Salidroside protects PC-12 cells against amyloid β -induced apoptosis by activation of the ERK1/2 and AKT signaling pathways. 2019 , 43, 1769-1777	8
761	Extracellular Vesicles from Mesenchymal Stem Cells Exert Pleiotropic Effects on Amyloid- β Inflammation, and Regeneration: A Spark of Hope for Alzheimer's Disease from Tiny Structures?. 2019 , 41, e1800199	18
760	Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease. 2019 , 67, 841-844	18
759	A blood-based signature of cerebrospinal fluid A β status. 2019 , 9, 4163	15
758	Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine. 2019 , 199, 173-187	48

757	The Role of Mitochondrial Dysfunction in the Progression of Alzheimer's Disease. 2018 , 25, 5578-5587	29
756	A Novel PEGylated Block Copolymer in New Age Therapeutics for Alzheimer's Disease. 2019 , 56, 6551-6565	12
755	Screening for Dementia Caused by Modifiable Lifestyle Choices Using Hybrid PET/MRI. 2019 , 3, 31-45	4
754	Development of Gleevec Analogues for Reducing Production of β Amyloid Peptides through Shifting β Cleavage of Amyloid Precursor Proteins. 2019 , 62, 3122-3134	3
753	Preliminary Report on the Feasibility and Efficacy of the Modified Atkins Diet for Treatment of Mild Cognitive Impairment and Early Alzheimer's Disease. 2019 , 68, 969-981	39
752	Understanding the Amyloid Hypothesis in Alzheimer's Disease. 2019 , 68, 493-510	33
751	DNA Aptamers Targeting BACE1 Reduce Amyloid Levels and Rescue Neuronal Deficiency in Cultured Cells. 2019 , 16, 302-312	6
750	Green Tea Extracts Attenuate Brain Dysfunction in High-Fat-Diet-Fed SAMP8 Mice. 2019 , 11,	9
749	Simulation Studies of Amyloidogenic Polypeptides and Their Aggregates. 2019 , 119, 6956-6993	74
748	Novel Sustainable-by-Design HDAC Inhibitors for the Treatment of Alzheimer's Disease. 2019 , 10, 671-676	10
747	Design and sample size considerations for Alzheimer's disease prevention trials using multistate models. 2019 , 16, 111-119	9
746	The potential of memory enhancement through modulation of perineuronal nets. 2019 , 176, 3611-3621	9
745	Sex as a biological variable in the pathology and pharmacology of neurodegenerative and neurovascular diseases. 2019 , 176, 4173-4192	19
744	Inhibiting A β toxicity in Alzheimer's disease by a pyridine amine derivative. 2019 , 168, 330-339	19
743	Are the neuroprotective effects of exercise training systemically mediated?. 2019 , 62, 94-101	44
742	Neuroprotective Effects of Spinosin on Recovery of Learning and Memory in a Mouse Model of Alzheimer's Disease. 2019 , 27, 71-77	12
741	Discovery of the First-in-Class GSK-3 β /HDAC Dual Inhibitor as Disease-Modifying Agent To Combat Alzheimer's Disease. 2019 , 10, 469-474	20
740	After-effects of repetitive anodal transcranial direct current stimulation on learning and memory in a rat model of Alzheimer's disease. 2019 , 161, 37-45	11

739	FDA position statement "Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry". 2019 , 5, 13-19	35
738	The Amazon rain forest plant <i>Uncaria tomentosa</i> (cat's claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. 2019 , 9, 561	23
737	Marmosets as a translational aging model-Introduction. 2019 , 81, e22912	5
736	Introduction: Alzheimer's Disease Pathology and Therapeutics. 2019 , 1-6	
735	The Role of Biomarkers in Alzheimer's Disease Drug Development. 2019 , 1118, 29-61	40
734	Ethical and Scientific Pitfalls Concerning Laboratory Research with Non-Human Primates, and Possible Solutions. 2018 , 9,	12
733	Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3. 2019 , 168, 58-77	31
732	Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies. 2020 , 257, 147-162	6
731	Misfolded proteins as a therapeutic target in Alzheimer's disease. 2019 , 118, 371-411	2
730	Mitochondria and Alzheimer's Disease: An Electron Microscopy Study. 2019 ,	1
729	Multidomain Interventions to Prevent Cognitive Impairment, Alzheimer's Disease, and Dementia: From FINGER to World-Wide FINGERS. 2020 , 7, 29-36	55
728	3Rs as part of preclinical neuropsychiatric translational crisis, and ARRIVE guidelines as part of solution. 2019 , 31, 348-349	2
727	Cognitive training for people with mild to moderate dementia. 2019 , 3, CD013069	68
726	Alzheimer's disease. 2019 , 167, 231-255	128
725	Editorial: Natural Products-Based Drugs: Potential Therapeutics Against Alzheimer's Disease and Other Neurological Disorders. 2019 , 10, 1417	23
724	Synthesis of new lophine-carbohydrate hybrids as cholinesterase inhibitors: cytotoxicity evaluation and molecular modeling. 2019 , 10, 2089-2101	7
723	Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment. 2019 , 9,	23
722	Anticholinesterase and Antioxidant Potential of Hydromethanolic Extract of (Rhamnaceae) Leaves on Scopolamine-Induced Memory and Cognitive Dysfunctions in Mice. 2019 , 2019, 4568401	11

721	Nature's Derivative(s) as Alternative Anti-Alzheimer's Disease Treatments. 2019 , 3, 279-297		7
720	How Big Data and High-performance Computing Drive Brain Science. 2019 , 17, 381-392		11
719	High exposure to statins decrease the risk of new-onset dementia: A nationwide population-based longitudinal cohort study. 2019 , 98, e16931		9
718	The Convergence of Alzheimer's Disease Pathogenesis Concepts. 2019 , 53, 896-903		5
717	Focused ultrasound-induced blood-brain barrier opening improves adult hippocampal neurogenesis and cognitive function in a cholinergic degeneration dementia rat model. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 110	9	29
716	The Environment Is a Key Factor in Determining the Anti-Amyloid Efficacy of EGCG. 2019 , 9,		20
715	Transcranial Direct Current Stimulation Improves Cognitive Function in Mild to Moderate Alzheimer Disease: A Meta-Analysis. 2019 , 33, 170-178		16
714	Future Treatment of Alzheimer Disease. 2019 ,		1
713	Application of molecular framework-based data-mining method in the search for beta-secretase 1 inhibitors through drug repurposing. 2019 , 37, 3674-3685		12
712	Calcium signalling: A common target in neurological disorders and neurogenesis. 2019 , 95, 25-33		23
711	Bax inhibitor 1 is a β -secretase-independent presenilin-binding protein. 2019 , 116, 141-147		8
710	Autonomic dysfunction in Parkinson disease and animal models. 2019 , 29, 397-414		20
709	Quantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer's disease. 2019 , 15, 429-440		35
708	Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies. 2019 , 218, 165-184		128
707	Contributions of a high-fat diet to Alzheimer's disease-related decline: A longitudinal behavioural and structural neuroimaging study in mouse models. 2019 , 21, 101606		27
706	Systematic Multi-Domain Alzheimer's Risk Reduction Trial (SMARRT): Study Protocol. 2019 , 70, S207-S220		14
705	The involvement of microglia in Alzheimer's disease: a new dog in the fight. 2019 , 176, 3533-3543		11
704	New approaches for the treatment of Alzheimer's disease. 2019 , 29, 125-133		53

703	Novel multitarget-directed ligands targeting acetylcholinesterase and β receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase. 2019 , 162, 234-248	28
702	Diet-induced insulin resistance elevates hippocampal glutamate as well as VGLUT1 and GFAP expression in APP/PS1 mice. 2019 , 148, 219-237	23
701	Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. 2019 , 18, 88-106	782
700	In vitro studies of the neuroprotective activities of astaxanthin and fucoxanthin against amyloid beta (A β) toxicity and aggregation. 2019 , 124, 215-224	52
699	Trodusquemine enhances A β aggregation but suppresses its toxicity by displacing oligomers from cell membranes. 2019 , 10, 225	69
698	Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease. 2019 , 40, 65-84	46
697	Neurotheranostics as personalized medicines. 2019 , 148, 252-289	36
696	Comparative study on neuroprotective activities of fucoidans from <i>Fucus vesiculosus</i> and <i>Undaria pinnatifida</i> . 2019 , 122, 255-264	20
695	Investigating alkyl nitrates as nitric oxide releasing precursors of multitarget acetylcholinesterase-monoamine oxidase B inhibitors. 2019 , 161, 292-309	28
694	Designed Polymer Micelle for Clearing Amyloid Protein Aggregates via Up-Regulated Autophagy. 2019 , 5, 390-401	24
693	Cardiovascular disease models: A game changing paradigm in drug discovery and screening. 2019 , 198, 3-26	88
692	<i>Convolvulus pluricaulis</i> (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAP τ) induced neurotoxicity in Alzheimer's disease <i>Drosophila</i> model. 2019 , 95, 115-122	20
691	Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach. 2019 , 37, 1282-1306	41
690	Delayed clearance of cerebrospinal fluid tracer from entorhinal cortex in idiopathic normal pressure hydrocephalus: A glymphatic magnetic resonance imaging study. 2019 , 39, 1355-1368	89
689	DL-3-n-Butylphthalide Inhibits NLRP3 Inflammasome and Mitigates Alzheimer's-Like Pathology via Nrf2-TXNIP-TrX Axis. 2019 , 30, 1411-1431	71
688	Impact evaluation of assistive technology support for the people with dementia. 2019 , 31, 180-192	9
687	A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. 2020 , 19, 1086-1130	23
686	Neurological diseases at the blood-brain barrier: Stemming new scientific paradigms using patient-derived induced pluripotent cells. 2020 , 1866, 165358	9

685	Towards more effective acetylcholinesterase inhibitors: a comprehensive modelling study based on human acetylcholinesterase protein-drug complex. 2020 , 38, 565-572	26
684	The Amyloid Phenomenon and Its Significance in Biology and Medicine. 2020 , 12,	65
683	Protein aggregation in cell biology: An aggregomics perspective of health and disease. 2020 , 99, 40-54	21
682	Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study. 2020 , 86, 54-63	69
681	Age-related neurodegenerative diseases. 2020 , 235, 3131-3141	9
680	Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer's disease. 2020 , 10, 646-666	8
679	The Impact of CRISPR-Cas9 on Age-related Disorders: From Pathology to Therapy. 2020 , 11, 895-915	2
678	Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges. 2020 , 9, 5-20	13
677	Lysosomal Dysregulation in the Murine App Model of Alzheimer's Disease. 2020 , 429, 143-155	7
676	Objective subtle cognitive difficulties predict future amyloid accumulation and neurodegeneration. 2020 , 94, e397-e406	50
675	Development of novel carbazole derivatives with effective multifunctional action against Alzheimer's diseases: Design, synthesis, in silico, in vitro and in vivo investigation. 2020 , 95, 103524	10
674	Ultrasonic waves effect on S-shaped Amyloids conformational dynamics by non-equilibrium molecular dynamics. 2020 , 96, 107518	5
673	Retinal Imaging in Alzheimer's Disease: In Search of the Holy Grail. 2020 , 127, 119-121	4
672	A high throughput drug screening paradigm using transgenic Caenorhabditis elegans model of Alzheimer's disease. 2020 , 4, 11-21	4
671	Neural stem cell therapy for neurovascular injury in Alzheimer's disease. 2020 , 324, 113112	35
670	Will We Have a Drug for Alzheimer's Disease by 2030? The View From Pharma. 2020 , 107, 79-81	5
669	Informed consent, therapeutic misconception, and clinical trials for Alzheimer's disease. 2020 , 35, 430-435	5
668	Interactions of a multifunctional di-triazole derivative with Alzheimer's A β monomer and A β protofibril: a systematic molecular dynamics study. 2020 , 22, 1543-1556	19

667	Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease. 2020 , 57, 331-338	19
666	Risks and benefits of unapproved disease-modifying treatments for neurodegenerative disease. 2020 , 94, e1-e14	16
665	βAmyloid Peptide: the Cell Compartment Multi-faceted Interaction in Alzheimer's Disease. 2020 , 37, 250-263	21
664	Sequential parallel comparison design with two coprimary endpoints. 2020 , 19, 243-254	0
663	In silico discovery of noteworthy multi-targeted acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. 2020 , 20, 351-366	2
662	Alzheimer's/Vascular Spectrum Dementia: Classification in Addition to Diagnosis. 2020 , 73, 63-71	18
661	An integrative review of exercise interventions among community-dwelling adults with Alzheimer's disease. 2020 , 15, e12287	1
660	PREDICT: a checklist for preventing preanalytical diagnostic errors in clinical trials. 2020 , 58, 518-526	13
659	A disease-modifying treatment for Alzheimer's disease: focus on the trans-sulfuration pathway. 2020 , 31, 319-334	0
658	Detection of gray matter microstructural changes in Alzheimer's disease continuum using fiber orientation. 2020 , 20, 362	8
657	Natural Compounds and Autophagy: Allies Against Neurodegeneration. 2020 , 8, 555409	27
656	The search for Alzheimer disease therapeutics - same targets, better trials?. 2020 , 16, 597-598	4
655	Potential Role for Herpesviruses in Alzheimer's Disease. 2020 , 78, 855-869	2
654	CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease-A Narrative Review. 2020 , 9, 419-434	11
653	Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures. 2020 , 6, e12071	3
652	Therapeutic Potential of TNF-β Inhibition for Alzheimer's Disease Prevention. 2020 , 78, 619-626	21
651	Can mindfulness-based interventions benefit people with dementia? Drawing on the evidence from a systematic review in populations with cognitive impairments. 2020 , 20, 1143-1156	6
650	Direct inhibition of Keap1-Nrf2 Protein-Protein interaction as a potential therapeutic strategy for Alzheimer's disease. 2020 , 103, 104172	14

649	Moving drug discoveries beyond the valley of death: the role of innovation ecosystems. 2020 , ahead-of-print,	3
648	Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. 2020 , 16, 440-456	80
647	Heavy Metals Exposure and Alzheimer's Disease and Related Dementias. 2020 , 76, 1215-1242	42
646	Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing. 2020 , 40, 2386-2426	25
645	Novel Multitarget Directed Tacrine Hybrids as Anti-Alzheimer's Compounds Improved Synaptic Plasticity and Cognitive Impairment in APP/PS1 Transgenic Mice. 2020 , 11, 4316-4328	1
644	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. 2020 , 21,	12
643	Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer's Disease. 2020 , 21,	2
642	Effects of repetitive paired associative stimulation on brain plasticity and working memory in Alzheimer's disease: a pilot randomized double-blind-controlled trial. 2020 , 1-13	4
641	Surface Modification of Microfluidic Blood-Brain-Barriers for Improved Screening of Small Molecules and Nanoparticles. 2020 , 12, 56753-56766	12
640	Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study. 2020 , 6, e12095	4
639	Dihydrophthalazinediones accelerate amyloid β peptide aggregation to nontoxic species. 2020 , 43, 1	
638	An β helix mimetic oligopyridylamide, ADH-31, modulates A β monomer aggregation and destabilizes protofibril structures: insights from molecular dynamics simulations. 2020 , 22, 28055-28073	3
637	Optical Coherence Tomography in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. 2020 , 11, 578698	4
636	Molecular estimation of neurodegeneration pseudotime in older brains. 2020 , 11, 5781	6
635	Aryldiazoquinoline based multifunctional small molecules for modulating A β aggregation and cholinesterase activity related to Alzheimer's disease.. 2020 , 10, 28827-28837	3
634	MAM and C99, key players in the pathogenesis of Alzheimer's disease. 2020 , 154, 235-278	5
633	Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review. 2020 , 8, e00622	3
632	Alzheimer's Disease, and Breast and Prostate Cancer Research: Translational Failures and the Importance to Monitor Outputs and Impact of Funded Research. 2020 , 10,	5

631	Altered age-linked regulation of plasma DYRK1A in elderly cognitive complainers (INSIGHT-preAD study) with high brain amyloid load. 2020 , 6, e12046	2
630	Endosomal Acid-Base Homeostasis in Neurodegenerative Diseases. 2020 , 1	3
629	Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics. 2020 , 180, 114187	20
628	More Than Selection Effects: Volunteering Is Associated With Benefits in Cognitive Functioning. 2020 , 75, 1741-1746	5
627	Dementia and its Impact on Minority Ethnic and Migrant Communities. 2020 , 423-439	
626	Alzheimer's disease in the gut-Major changes in the gut of 5xFAD model mice with ApoA1 as potential key player. 2020 , 34, 11883-11899	6
625	Stem Cell Therapy for Alzheimer's Disease. 2020 , 1266, 39-55	9
624	Does size matter? The relationship between predictive power of single-subject morphometric networks to spatial scale and edge weight. 2020 , 225, 2475-2493	3
623	Mangosteen Pericarp and Its Bioactive Xanthenes: Potential Therapeutic Value in Alzheimer's Disease, Parkinson's Disease, and Depression with Pharmacokinetic and Safety Profiles. 2020 , 21,	14
622	Hippocampal alterations in glutamatergic signaling during amyloid progression in APP/PS1 mice. 2020 , 10, 14503	5
621	Rhesus macaques as a tractable physiological model of human ageing. 2020 , 375, 20190612	10
620	Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines. 2020 , 11, 1967	0
619	Multifunctional nano-enabled delivery systems in Alzheimer's disease management. 2020 , 8, 5538-5554	5
618	Use of galantamine in the treatment of Alzheimer's disease and strategies to optimize its biosynthesis using the in vitro culture technique. 2020 , 143, 13-29	5
617	Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papers.. 2020 , 4, e100041	8
616	GSK3-ARC/Arg3.1 and GSK3-Wnt signaling axes trigger amyloid- β accumulation and neuroinflammation in middle-aged Shugoshin 1 mice. 2020 , 19, e13221	6
615	QT interval prolongation and with donepezil, rivastigmine and galantamine. 2020 , 11, 2042098620942416	3
614	Predicting Alzheimer's Disease Using Driving Simulator Data. 2020 , 2020, 5432-5435	1

613	Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease. 2020 , 13,		13
612	Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. 2020 , 52, 1122-1131		75
611	T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 105	9	8
610	Prelimbic Cortical Stimulation Improves Spatial Memory Through Distinct Patterns of Hippocampal Gene Expression in Aged Rats. 2020 , 17, 2054-2068		4
609	Reply to: APP gene copy number changes reflect exogenous contamination. 2020 , 584, E29-E33		5
608	REDD1 Is Involved in Amyloid Induced Synaptic Dysfunction and Memory Impairment. 2020 , 21,		1
607	Model organism development and evaluation for late-onset Alzheimer's disease: MODEL-AD. 2020 , 6, e12110		21
606	An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer's disease. 2020 , 12,		28
605	Biomarkers: Our Path Towards a Cure for Alzheimer Disease. 2020 , 15, 1177271920976367		9
604	An Overview of Astrocyte Responses in Genetically Induced Alzheimer's Disease Mouse Models. 2020 , 9,		8
603	Vitamin B3-Based Biologically Active Compounds as Inhibitors of Human Cholinesterases. 2020 , 21,		4
602	Genetic Factors of Alzheimer's Disease Modulate How Diet is Associated with Long-Term Cognitive Trajectories: A UK Biobank Study. 2020 , 78, 1245-1257		3
601	Induced expression of P-gp and BCRP transporters on brain endothelial cells using transferrin functionalized nanostructured lipid carriers: A first step of a potential strategy for the treatment of Alzheimer's disease. 2020 , 591, 120011		10
600	Network pharmacology used to decode potential active ingredients in <i>Ferula assafoetida</i> and mechanisms for the application to Alzheimer's disease. 2020 , 7, 199-209		1
599	Improving Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Are Irreversible Inhibitors the Future?. 2020 , 21,		23
598	Anodal Transcranial Direct Current Stimulation Can Improve Spatial Learning and Memory and Attenuate A β Burden at the Early Stage of Alzheimer's Disease in APP/PS1 Transgenic Mice. 2020 , 12, 134		8
597	β Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse β Secretase modulators do not. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 61	9	1
596	Deficits in Mitochondrial Spare Respiratory Capacity Contribute to the Neuropsychological Changes of Alzheimer's Disease. 2020 , 10,		10

595	Combination Drug Therapy for the Management of Alzheimer's Disease. 2020 , 21,	55
594	Mosaic Somatic Gene Recombination as a Potentially Unifying Hypothesis for Alzheimer's Disease. 2020 , 11, 390	9
593	High-Throughput Screening at the Membrane Interface Reveals Inhibitors of Amyloid- β 2020 , 59, 2249-2258	21
592	Human Gut-Microbiota Interaction in Neurodegenerative Disorders and Current Engineered Tools for Its Modeling. 2020 , 10, 297	18
591	Collagen hydrogel confinement of Amyloid- β accelerates aggregation and reduces cytotoxic effects. 2020 , 112, 164-173	9
590	Amelioration of BPSD-Like Phenotype and Cognitive Decline in SAMP8 Mice Model Accompanied by Molecular Changes after Treatment with I-Imidazoline Receptor Ligand MCR5. 2020 , 12,	2
589	Targeting Infectious Agents as a Therapeutic Strategy in Alzheimer's Disease. 2020 , 34, 673-695	10
588	Benchmarking biopharmaceutical process development and manufacturing cost contributions to R&D. 2020 , 12, 1754999	14
587	Development and Validation of a Nomogram for Predicting the 6-Year Risk of Cognitive Impairment Among Chinese Older Adults. 2020 , 21, 864-871.e6	3
586	Structural Brain Magnetic Resonance Imaging to Rule Out Comorbid Pathology in the Assessment of Alzheimer's Disease Dementia: Findings from the Ontario Neurodegenerative Disease Research Initiative (ONDRI) Study and Clinical Trials Over the Past 10 Years. 2020 , 74, 747-757	4
585	Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event-based model of disease progression. 2020 , 16, 965-973	13
584	Downregulated Platelet miR-1233-5p in Patients with Alzheimer's Pathologic Change with Mild Cognitive Impairment is Associated with β -Induced Platelet Activation via P-Selectin. 2020 , 9,	5
583	CaSR Antagonist (Calcilytic) NPS 2143 Hinders the Release of Neuroinflammatory IL-6, Soluble ICAM-1, RANTES, and MCP-2 from β -Exposed Human Cortical Astrocytes. 2020 , 9,	4
582	A Systematic Review of Clinical Studies on the Effect of Psychoactive Cannabinoids in Psychiatric Conditions in Alzheimer Dementia. 2020 , 27, e249-e269	7
581	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. 2020 , 49, 22-37	4
580	Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease. 2020 , 57, 3258-3272	14
579	Models of Neurodegenerative Diseases. 2020 , 8, 328	66
578	AMBAR, an Encouraging Alzheimer's Trial That Raises Questions. 2020 , 11, 459	6

577	Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part II. 2020 , 21, 15	1
576	Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer's Disease. 2020 , 74, 55-63	6
575	Interaction of oxidative stress and neurotrauma in ALDH2 mice causes significant and persistent behavioral and pro-inflammatory effects in a tractable model of mild traumatic brain injury. 2020 , 32, 101486	8
574	Mechanically and Electrically Enhanced Polyurethane-poly(3,4-ethylenedioxythiophene) Conductive Foams with Aligned Pore Structures Promote MC3T3-E1 Cell Growth and Proliferation. 2020 , 2, 1482-1490	4
573	Prevention of multiple system atrophy using human bone marrow-derived mesenchymal stem cells by reducing polyamine and cholesterol-induced neural damages. 2020 , 11, 63	
572	Engineering of fluorescent or photoactive Trojan probes for detection and eradication of β Amyloids. 2020 , 27, 917-926	
571	A human induced pluripotent stem cell-derived cortical neuron human-on-a chip system to study A β and tau-induced pathophysiological effects on long-term potentiation. 2020 , 6, e12029	2
570	Improving preclinical to clinical translation in Alzheimer's disease research. 2020 , 6, e12038	7
569	β Amyloid and tau drive early Alzheimer's disease decline while glucose hypometabolism drives late decline. 2020 , 3, 352	23
568	Up-regulation of neprilysin mediates the protection of fructo-oligosaccharides against Alzheimer's disease. 2020 , 11, 6565-6572	1
567	Exploring different approaches to improve the success of drug discovery and development projects: a review. 2020 , 6,	24
566	Rationally Designed Antibodies as Research Tools to Study the Structure-Toxicity Relationship of Amyloid- β Oligomers. 2020 , 21,	7
565	Protocol of Aerobic Exercise and Cognitive Health (REACH): A Pilot Study. 2020 , 4, 107-121	5
564	Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA-Protein Interaction. 2020 , 11, 2277-2285	7
563	Nanoengineered biomaterials for neurodegenerative disorders. 2020 , 713-734	1
562	Intra-gastrointestinal amyloid- β -42 oligomers perturb enteric function and induce Alzheimer's disease pathology. 2020 , 598, 4209-4223	29
561	Genetic Dissection of Alzheimer's Disease Using Models. 2020 , 21,	10
560	APOE-amyloid interaction: Therapeutic targets. 2020 , 138, 104784	27

559	Bilingualism Is Associated with a Delayed Onset of Dementia but Not with a Lower Risk of Developing it: a Systematic Review with Meta-Analyses. 2020 , 30, 1-24	14
558	Should we move dementia research funding from a cure to its care?. 2020 , 20, 303-305	5
557	Abrogation of type-I interferon signalling alters the microglial response to A β 2020 , 10, 3153	8
556	Donepezil-based hybrids as multifunctional anti-Alzheimer's disease chelating agents: Effect of positional isomerization. 2020 , 206, 111039	8
555	Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotonergic 5-HT receptors activities for the treatment of Alzheimer's disease. 2020 , 10, 3014	17
554	Mindfulness improves inflammatory biomarker levels in older adults with mild cognitive impairment: a randomized controlled trial. 2020 , 10, 21	32
553	Design, Synthesis, and In Vitro Evaluation of Hydroxybenzimidazole-Donepezil Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease. 2020 , 25,	15
552	OCIAD1 contributes to neurodegeneration in Alzheimer's disease by inducing mitochondria dysfunction, neuronal vulnerability and synaptic damages. 2020 , 51, 102569	5
551	Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. 2020 , 107, 796-805	7
550	New Insights Into the Pathogenesis of Alzheimer's Disease. 2019 , 10, 1312	83
549	The Paradoxical Effect of Deep Brain Stimulation on Memory. 2020 , 11, 179-190	8
548	Deep Eutectic Solvents as Effective Reaction Media for the Synthesis of 2-Hydroxyphenylbenzimidazole-based Scaffolds en Route to Donepezil-Like Compounds. 2020 , 25,	13
547	Informant Reporting in Mild Cognitive Impairment: Sources of Discrepancy on the Functional Activities Questionnaire. 2020 , 26, 503-514	12
546	Insulin resistance and impaired lipid metabolism as a potential link between diabetes and Alzheimer's disease. 2020 , 81, 194-205	9
545	Advances in protein misfolding, amyloidosis and its correlation with human diseases. 2020 , 10, 193	3
544	Neuroprotective Properties of Resveratrol and Its Derivatives-Influence on Potential Mechanisms Leading to the Development of Alzheimer's Disease. 2020 , 21,	9
543	Fluorinated Molecules and Nanotechnology: Future 'Avengers' against the Alzheimer's Disease?. 2020 , 21,	5
542	[Toward a preventive management Alzheimer's disease]. 2020 , 204, 583-588	

541	N-alkylpiperidine carbamates as potential anti-Alzheimer's agents. 2020 , 197, 112282			15
540	Aromatic Esters of the Crinane Amaryllidaceae Alkaloid Ambelline as Selective Inhibitors of Butyrylcholinesterase. 2020 , 83, 1359-1367			13
539	Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 38	9		5
538	All-trans retinoic acid induces reprogramming of canine dedifferentiated cells into neuron-like cells. 2020 , 15, e0229892			6
537	A Systematic Bioinformatics Workflow With Meta-Analytics Identified Potential Pathogenic Factors of Alzheimer's Disease. 2020 , 14, 209			4
536	The application of in vitro-derived human neurons in neurodegenerative disease modeling. 2021 , 99, 124-140			14
535	Inter-individual differences in the responses to aerobic exercise in Alzheimer's disease: Findings from the FIT-AD trial. 2021 , 10, 65-72			4
534	Reactive Oxygen Species and Their Impact in Neurodegenerative Diseases: Literature Landscape Analysis. 2021 , 34, 402-420			24
533	Design and Validation of Liposomal ApoE2 Gene Delivery System to Evade Blood-Brain Barrier for Effective Treatment of Alzheimer's Disease. 2021 , 18, 714-725			27
532	Turning Donepezil into a Multi-Target-Directed Ligand through a Merging Strategy. 2021 , 16, 187-198			4
531	Requirements for Animal Experiments: Problems and Challenges. 2021 , 17, e2004182			12
530	AlphaScreen Identifies MSUT2 Inhibitors for Tauopathy-Targeting Therapeutic Discovery. 2021 , 26, 400-409			0
529	Development of a robust crystallization platform for immune receptor TREM2 using a crystallization chaperone strategy. 2021 , 179, 105796			3
528	Cannabis Use among Persons with Dementia and Their Caregivers: Lighting up an Emerging Issue for Clinical Gerontologists. 2021 , 44, 42-52			0
527	Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome. 2021 , 17, 595-604			5
526	Role of reactive oxygen species in the progression of Alzheimer's disease. 2021 , 26, 794-803			17
525	Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions. 2021 , 41, 1427-1473			26
524	Akt and calcium-permeable AMPA receptor are involved in the effect of pinoresinol on amyloid Induced synaptic plasticity and memory deficits. 2021 , 184, 114366			2

523	Orally Administered Benzofuran Derivative Disaggregated A β Plaques and Oligomers in the Brain of 5XFAD Alzheimer Transgenic Mouse. 2021 , 12, 99-108	2
522	TDMQ20, a Specific Copper Chelator, Reduces Memory Impairments in Alzheimer's Disease Mouse Models. 2021 , 12, 140-149	8
521	Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6. 2021 , 12, 178-196	1
520	Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. 2021 , 33, 3-13	5
519	Neuronal degeneration and cognitive impairment can be prevented via the normalization of mitochondrial dynamics. 2021 , 163, 105246	2
518	l imidazoline receptor modulation protects aged SAMP8 mice against cognitive decline by suppressing the calcineurin pathway. 2021 , 43, 965-983	3
517	Comparison between touchscreen operant chambers and water maze to detect early prefrontal dysfunction in mice. 2021 , 20, e12695	4
516	Memory Support System training in mild cognitive impairment: Predictors of learning and adherence. 2021 , 31, 92-104	7
515	Multi-Targeting Tacrine Conjugates with Cholinesterase and Amyloid-Beta Inhibitory Activities: New Anti-Alzheimer's Agents. 2021 , 18, e2000083	1
514	Amyloid Beta. 2021 , 1-17	
513	Machine learning approaches to predicting amyloid status using data from an online research and recruitment registry: The Brain Health Registry. 2021 , 13, e12207	0
512	Efficacy of simultaneous aerobic exercise and cognitive training in subjective cognitive decline: study protocol for randomized controlled trial of the Exergames Study. 2021 , 22, 14	2
511	Feasibility and Preliminary Efficacy of a Multimodal Approach to Increase Physical Activity in Older Adults With Memory Complaints: The Education for Action Study. 2021 , 1-13	1
510	Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome. 2021 , 17, e1009224	10
509	Apolipoprotein E allele 4 effects on Single-Subject Gray Matter Networks in Mild Cognitive Impairment. 2021 , 32, 102799	
508	Nanotechnology Therapy for Alzheimer's Disease Memory Impairment Attenuation. 2021 , 22,	
507	Early Detection of Alzheimer's Disease with Low-Cost Neuropsychological Tests: A Novel Predict-Diagnose Approach using Recurrent Neural Networks.	0
506	Aging in nonhuman primates. 2021 , 237-248	

505	Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer's dementia. 2021 , 7, e12106	4
504	New approaches to symptomatic treatments for Alzheimer's disease. 2021 , 16, 2	35
503	Hydrogen sulfide is neuroprotective in Alzheimer's disease by sulphydrating GSK3 β and inhibiting Tau hyperphosphorylation. 2021 , 118,	34
502	Who funds Alzheimer's disease drug development?. 2021 , 7, e12185	2
501	A systems-biology clinical trial of a personalized multimodal lifestyle intervention for early Alzheimer's disease. 2021 , 7, e12191	2
500	microRNAs as Early Biomarkers of Alzheimer's Disease: A Synaptic Perspective. 2021 , 10,	13
499	Antimicrobial β -defensins as multi-target inhibitors against amyloid formation and microbial infection. 2021 , 12, 9124-9139	9
498	Discovery of 8-prenylnaringenin from hop (L.) as a potent monoacylglycerol lipase inhibitor for treatments of neuroinflammation and Alzheimer's disease.. 2021 , 11, 31062-31072	0
497	Dendrimer-tesaglitazar conjugate induces a phenotype shift of microglia and enhances β amyloid phagocytosis. 2021 , 13, 939-952	7
496	The biological pathways of Alzheimer disease: a review. 2021 , 8, 86-132	33
495	The Role of Natural Antioxidants in the Prevention of Dementia-Where Do We Stand and Future Perspectives. 2021 , 13,	9
494	Delineating the Role of Mitophagy Inducers for Alzheimer Disease Patients. 2021 , 12, 852-867	2
493	Dysregulated gene-associated biomarkers for Alzheimer's disease and aging. 2021 , 12, 83-95	3
492	Association between exenatide use and incidence of Alzheimer's disease. 2021 , 7, e12139	1
491	Comprehensive review of Alzheimer's disease drugs (conventional, newer, and plant-derived) with focus on Bacopa monnieri. 2021 , 227-248	
490	Microenvironment-tailored nanoassemblies for the diagnosis and therapy of neurodegenerative diseases. 2021 , 13, 10197-10238	2
489	Presence of a mutation in PSEN1 or PSEN2 gene is associated with an impaired brain endothelial cell phenotype in vitro. 2021 , 18, 3	10
488	Design, synthesis, and bio-evaluation of new isoindoline-1,3-dione derivatives as possible inhibitors of acetylcholinesterase. 2021 , 16, 482-492	0

487	GenoRisk: A polygenic risk score for Alzheimer's disease. 2021 , 7, e12211		0
486	The relationship of semantic intrusions to different etiological subtypes of MCI and cognitively healthy older adults. 2021 , 13, e12192		1
485	Sporadic Alzheimer's triad. 2021 , 65-77		
484	Medicinal Plants in Uganda as Potential Therapeutics against Neurological Disorders. 2021 , 421-443		
483	From Combinations to Single-Molecule Polypharmacology-Cromolyn-Ibuprofen Conjugates for Alzheimer's Disease. 2021 , 26,		1
482	CSF AB8 levels are associated with Alzheimer-related decline: implications for β secretase modulators.		1
481	High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases. 2021 , 8,		47
480	Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. 2021 , 31, 1900-1912		13
479	Alzheimer's disease research: past approaches and future directions. 2021 , 17, 34-39		
478	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 47	9	14
477	Feasibility and acceptability of a multi-domain intervention to increase Mediterranean diet adherence and physical activity in older UK adults at risk of dementia: protocol for the MedEx-UK randomised controlled trial. 2021 , 11, e042823		2
476	Targeted screening for Alzheimer's disease clinical trials using data-driven disease progression models.		0
475	Nutrition as Metabolic Treatment for Anxiety. 2021 , 12, 598119		4
474	Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach. 2021 , 99, 1308-1324		3
473	A promising new β secretase modulator for Alzheimer's disease. 2021 , 218,		0
472	Advances in Central Nervous System Organoids: A Focus on Organoid-Based Models for Motor Neuron Disease. 2021 , 27, 213-224		6
471	Chemical similarity assisted search for acetylcholinesterase inhibitors: Molecular modeling and evaluation of their neuroprotective properties. 2021 , 174, 466-476		2
470	The Function of Selenium in Central Nervous System: Lessons from MsrB1 Knockout Mouse Models. 2021 , 26,		0

469	Neuroprotective Roles of the Reverse Transsulfuration Pathway in Alzheimer's Disease. 2021 , 13, 659402	6
468	A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 62	9 28
467	Deep Brain Stimulation for Alzheimer's Disease: Stimulation Parameters and Potential Mechanisms of Action. 2021 , 13, 619543	10
466	Astrocyte-neuron interplay is critical for Alzheimer's disease pathogenesis and is rescued by TRPA1 channel blockade.	
465	Association between Previous Statin Use and Alzheimer's Disease: A Nested Case-Control Study Using a National Health Screening Cohort. 2021 , 11,	3
464	The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. 2021 , 29, 949-972	3
463	Antinödejeneratif 5-söstitö 2,4-tiyazolidindion Töevlerin Kuantum Kimyasal Öcelemesi.	
462	Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles. 2021 , 8, e2002085	8
461	Value-Generating Exploratory Trials in Neurodegenerative Dementias. 2021 , 96, 944-954	5
460	Protective genes and pathways in Alzheimer's disease: moving towards precision interventions. 2021 , 16, 29	12
459	Utilising Induced Pluripotent Stem Cells in Neurodegenerative Disease Research: Focus on Glia. 2021 , 22,	3
458	Sustainable Drug Discovery of Multi-Target-Directed Ligands for Alzheimer's Disease. 2021 , 64, 4972-4990	18
457	Precision Nutrition for Alzheimer's Prevention in Carriers. 2021 , 13,	8
456	Cognition. 1-76	
455	Anti-Alzheimer's Molecules Derived from Marine Life: Understanding Molecular Mechanisms and Therapeutic Potential. 2021 , 19,	10
454	Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease. 2021 , 17, 1487-1498	6
453	Peptidotriazolamers Inhibit A β (1-42) Oligomerization and Cross a Blood-Brain-Barrier Model. 2021 , 86, 840-851	0
452	Emerging Brain-Pathophysiology-Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains-on-a-Chip. 2021 , 10, e2002119	7

451	Neoline Improves Memory Impairment and Reduces Amyloid- β Level and Tau Phosphorylation Through AMPK Activation in the Mouse Alzheimer's Disease Model. 2021 , 81, 507-516	1
450	A genome-wide association study in human lymphoblastoid cells supports safety of mitochondrial complex I inhibitor. 2021 , 58, 83-94	2
449	The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy. 2021 , 5, e12504	3
448	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. 2021 , 82, 71-105	7
447	Intracerebroventricularly Injected Streptozotocin Exerts Subtle Effects on the Cognitive Performance of Long-Evans Rats. 2021 , 12, 662173	1
446	Fungally Derived Isoquinoline Demonstrates Inducer-Specific Tau Aggregation Inhibition. 2021 , 60, 1658-1669	2
445	Allicin ameliorates aluminium- and copper-induced cognitive dysfunction in Wistar rats: relevance to neuro-inflammation, neurotransmitters and A β analysis. 2021 , 26, 495-510	1
444	Squalamine and Its Derivatives Modulate the Aggregation of Amyloid- β and β Synuclein and Suppress the Toxicity of Their Oligomers. 2021 , 15, 680026	11
443	Retinal Changes in Transgenic Mouse Models of Alzheimer's Disease. 2021 , 18, 89-102	1
442	What's not in the news headlines or titles of Alzheimer disease articles? #InMice. 2021 , 19, e3001260	1
441	Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer's Disease Mouse Model. 2021 , 64, 9302-9320	7
440	Nanomaterials toward the treatment of Alzheimer's disease: Recent advances and future trends. 2021 , 32, 1857-1868	9
439	Reassessment of Pioglitazone for Alzheimer's Disease. 2021 , 15, 666958	5
438	From Kuru to Alzheimer: A personal outlook. 2021 , 30, 1776-1792	3
437	Effect of Chronic Stress Present in Fibroblasts Derived from Patients with a Sporadic Form of AD on Mitochondrial Function and Mitochondrial Turnover. 2021 , 10,	4
436	Surface Plasmon Resonance Assay for Identification of Small Molecules Capable of Inhibiting A β Aggregation. 2021 , 13, 27845-27855	1
435	Design, synthesis and in-vitro evaluation of fluorinated triazoles as multi-target directed ligands for Alzheimer disease. 2021 , 42, 127999	1
434	Reporting amyloid beta levels via bioluminescence imaging with amyloid reservoirs in Alzheimer's disease models.	

433	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. 2021 , 27, 1187-1196	51
432	Astrocyte-neuron interplay is critical for Alzheimer's disease pathogenesis and is rescued by TRPA1 channel blockade. 2021 ,	2
431	The informed road map to prevention of Alzheimer Disease: A call to arms. 2021 , 16, 49	7
430	Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study. 2021 , 13, 713726	18
429	Genetically engineered exosomes display RVG peptide and selectively enrich a neprilysin variant: a potential formulation for the treatment of Alzheimer's disease. 2021 , 29, 1128-1138	2
428	The Microbiota-Gut-Brain Axis in Health and Disease and Its Implications for Translational Research. 2021 , 15, 698172	6
427	Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression. 2021 , 134, 1709-1719	0
426	The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain. 2021 , 13, 654931	9
425	The piperine derivative HJ105 inhibits A β -induced neuroinflammation and oxidative damage via the Keap1-Nrf2-TXNIP axis. 2021 , 87, 153571	5
424	CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. 2021 ,	3
423	Defective Autophagy and Mitophagy in Alzheimer's Disease: Mechanisms and Translational Implications. 2021 , 58, 5289-5302	2
422	EVOO Polyphenols Relieve Synergistically Autophagy Dysregulation in a Cellular Model of Alzheimer's Disease. 2021 , 22,	5
421	Alzheimer's Disease and Oral-Systemic Health: Bidirectional Care Integration Improving Outcomes.. 2021 , 2, 674329	2
420	On the design of early-phase Alzheimer's disease clinical trials with cerebrospinal fluid tau outcomes. 2021 , 18, 714-723	0
419	Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model. 2021 , 22,	0
418	Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies. 2021 , 46, 2832-2851	3
417	Amyloid β -Binding Bifunctional Chelators with Favorable Lipophilicity for Cu Positron Emission Tomography Imaging in Alzheimer's Disease. 2021 , 60, 12610-12620	2
416	The outcomes of small-molecule kinase inhibitors and the role of ROCK2 as a molecular target for the treatment of Alzheimer's disease. 2021 ,	

- 415 Quantum dots as a theranostic approach in Alzheimer's disease: a systematic review. **2021**, 16, 1595-1611 7
- 414 Evaluate and Optimize Cell-Free RNA Extraction Methods to Apply for Alzheimer's Disease Biomarkers Detection. **2022**, 591-609
- 413 A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease. **2021**, 83, 1537-1552 17
- 412 Feedback control of protein aggregation. **2021**, 155, 064102 0
- 411 Exposure to Air Pollution in Relation to Risk of Dementia and Related Outcomes: An Updated Systematic Review of the Epidemiological Literature. **2021**, 129, 96001 14
- 410 Acetylcholine esterase inhibitory activity of green synthesized nanosilver by naphthopyrones isolated from marine-derived *Aspergillus niger*. **2021**, 16, e0257071 1
- 409 Harnessing Neuroplasticity to Promote Brain Health in Aging Adults: the MOVE-Cog Intervention Study Protocol (Preprint).
- 408 Integrating Transcriptomics, Genomics, and Imaging in Alzheimer's Disease: A Federated Model.
- 407 The costs of developing treatments for Alzheimer's disease: A retrospective exploration. **2021**, 3
- 406 Mindfulness Awareness Practice (MAP) to Prevent Dementia in Older Adults with Mild Cognitive Impairment: Protocol of a Randomized Controlled Trial and Implementation Outcomes. **2021**, 18, 1
- 405 Kif11 overexpression rescues cognition, long-term potentiation, and spine defects in mouse and cell models of Alzheimer's disease.
- 404 Microglia Mediate the Occurrence and Development of Alzheimer's Disease Through Ligand-Receptor Axis Communication. **2021**, 13, 731180 2
- 403 Sex-Specific Cross Tissue Meta-Analysis Identifies Immune Dysregulation in Women With Alzheimer's Disease. **2021**, 13, 735611 7
- 402 Cyanobiphenyls: Novel H receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer's disease. **2021**, 114, 105129 1
- 401 Neuronal Deposition of Amyloid- β Oligomers and Hyperphosphorylated Tau Is Closely Connected with Cognitive Dysfunction in Aged Dogs. **2021**, 5, 749-760 0
- 400 Harnessing Neuroplasticity to Promote Brain Health in Aging Adults: Protocol for the MOVE-Cog Intervention Study. **2021**, 10, e33589 0
- 399 Mitochondria in the Cerebral and Cerebellar Cortex in Alzheimer's Disease, Target for a Therapeutic Approach.
- 398 Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics. **2021**, 71, 103503 3

- 397 Cashew Nut Shell Liquid (CNSL) as a Source of Drugs for Alzheimer's Disease. **2021**, 26, 0
- 396 T2 heterogeneity as an in vivo marker of microstructural integrity in medial temporal lobe subfields in ageing and mild cognitive impairment. **2021**, 238, 118214
- 395 Scoping Review of Prospective Clinical Studies, Projects, and Clinical Study Protocol for Korean Medicine Treatment on Dementia. **2021**, 42, 99-118
- 394 The Discovery of Peptide Macrocycle Rescuers of Pathogenic Protein Misfolding and Aggregation by Integrating SICLOPPS Technology and Ultrahigh-Throughput Screening in Bacteria. **2022**, 2371, 215-246 0
- 393 Alternative platelet activation pathways and their role in neurodegenerative diseases. **2021**, 159, 105512 1
- 392 JM-20 treatment prevents neuronal damage and memory impairment induced by aluminum chloride in rats. **2021**, 87, 70-85 1
- 391 Deciphering the role of PGC-1 β in neurological disorders: from mitochondrial dysfunction to synaptic failure. **2022**, 17, 237-245 0
- 390 Multifunctional peptide-assembled micelles for simultaneously reducing amyloid- β and reactive oxygen species. **2021**, 12, 6449-6457 8
- 389 Interdisciplinary Research in Alzheimer's Disease and the Roles International Societies Can Play. **2021**, 12, 36-41 6
- 388 Machine Learning Application in COVID-19 Drug Development. **2021**, 229-244
- 387 Predicting the Potency of Anti-Alzheimer's Drug Combinations Using Machine Learning. **2021**, 9, 264 0
- 386 Alzheimer's Disease Pharmacology. **2021**, 1
- 385 Nanoparticle-based colorimetric sensors to detect neurodegenerative disease biomarkers. **2021**, 9, 6983-7007 0
- 384 Thermosensitive chitosan-based hydrogels supporting motor neuron-like NSC-34 cell differentiation. **2021**, 9, 7492-7503 2
- 383 Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: A single and multiple ascending dose phase 1b/2a clinical trial. **2020**, 6, e12107 7
- 382 Effects of physical activities on dementia-related biomarkers: A systematic review of randomized controlled trials. **2020**, 6, e12109 2
- 381 Translational animal models for Alzheimer's disease: An Alzheimer's Association Business Consortium Think Tank. **2020**, 6, e12114 16
- 380 Behavioral Medicine and the Benefits of Healthcare: A Critical Appraisal and the Need for Exnovation. **2018**, 1069-1086 1

379	Epidemiology of Dementia: The Burden on Society, the Challenges for Research. 2018 , 1750, 3-14	25
378	Alzheimer's Disease Therapeutic Approaches. 2020 , 1195, 105-116	12
377	The Aged Dog as a Natural Model of Alzheimer's Disease Progression. 2017 , 69-92	2
376	The Global Economic Impact of Neurodegenerative Diseases: Opportunities and Challenges. 2020 , 333-345	6
375	Induced Pluripotent Stem Cell-Derived Astroglia: A New Tool for Research Towards the Treatment of Alzheimer's Disease. 2019 , 1175, 383-405	4
374	A systems biology approach for studying neurodegenerative diseases. 2020 , 25, 1146-1159	8
373	Diagnosis of Alzheimer's Disease using Structural MRI and Convolution Neural Network. 2020 , 185, 03037	1
372	A novel approach to derive human midbrain-specific organoids from neuroepithelial stem cells.	2
371	The causes and consequences of Alzheimer's disease: phenome-wide evidence from Mendelian randomization.	4
370	Network-based Translation of GWAS Findings to Pathobiology and Drug Repurposing for Alzheimer's Disease.	8
369	Acoustofluidic Assembly of 3D Neurospheroids to Model Alzheimer's Disease.	1
368	Sex-Specific Cross Tissue Meta-Analysis Identifies Immune Dysregulation in Women with Alzheimer's Disease.	3
367	Rhesus macaques as a tractable physiological model of human ageing.	1
366	Epoxy fatty acid dysregulation and neuroinflammation in Alzheimer's disease is resolved by a soluble epoxide hydrolase inhibitor.	3
365	A molecular network of the aging brain implicates INPPL1 and PLXNB1 in Alzheimer's disease.	3
364	The Amyloid Clearance Defect in ApoE4 Astrocytes is Corrected by Epigenetic Restoration of NHE6.	0
363	Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson's disease.	3
362	Meta-analysis of the human brain transcriptome identifies heterogeneity across human AD coexpression modules robust to sample collection and methodological approach.	14

361	Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases.	21
360	Reply: Evidence that APP gene copy number changes reflect recombinant vector contamination.	3
359	Ketogenic Diet for the Treatment and Prevention of Dementia: A Review. 2021 , 34, 3-10	21
358	Comprehensive analysis of PM20D1 QTL in Alzheimer's disease. 2020 , 12, 20	7
357	Putative autoantibodies in the cerebrospinal fluid of Alzheimer's disease patients. 2019 , 8, 1900	11
356	Likelihood of Null Effects of Large NHLBI Clinical Trials Has Increased over Time. 2015 , 10, e0132382	141
355	Drug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data Mining. 2016 , 11, e0168812	62
354	Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network. 2016 , 3, 114-120	31
353	APP Overexpression Causes Aβ-independent Neuronal Death through Intrinsic Apoptosis Pathway. 2016 , 3,	17
352	Prodromes and Preclinical Detection of Brain Diseases: Surveying the Ethical Landscape of Predicting Brain Health. 2019 , 6,	3
351	Assessment of Acetylcholinesterase Inhibitor by Bacopa Monnieri and Acephate in Hippocampus of Chick Brain for Impediment of Alzheimer's Disease. 2016 , 4,	1
350	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. 2020 , 42, 431-441	18
349	[A review of drugs for treatment of Alzheimer's disease in clinical trials: main trends]. 2016 , 116, 77-87	4
348	Serial position effects differ between Alzheimer's and vascular features in mild cognitive impairment. 2018 , 10, 3866-3880	3
347	The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β peptide folding into β-sheet to form oligomers. 2017 , 8, 41154-41165	4
346	Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. 2018 , 9, 5614-5626	8
345	Brain Drug Delivery: Overcoming the Blood-brain Barrier to Treat Tauopathies. 2020 , 26, 1448-1465	0
344	The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimer's Disease. 2020 , 26, 1345-1355	1

343	Human Amylin: From Pathology to Physiology and Pharmacology. 2019 , 20, 944-957	12
342	Strategies Targeting Soluble β Amyloid Oligomers and their Application to Early Diagnosis of Alzheimer's Disease. 2019 , 16, 1132-1142	2
341	Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. 2020 , 17, 285-296	7
340	Target Enzyme in Alzheimer's Disease: Acetylcholinesterase Inhibitors. 2019 , 19, 264-275	53
339	Future Perspective of Diabetic Animal Models. 2020 , 20, 25-38	10
338	A Remote Intervention to Prevent or Delay Cognitive Impairment in Older Adults: Design, Recruitment, and Baseline Characteristics of the Virtual Cognitive Health (VC Health) Study. 2018 , 7, e11368	13
337	Internet Searches and Their Relationship to Cognitive Function in Older Adults: Cross-Sectional Analysis. 2017 , 19, e307	16
336	Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology?. 2019 , 4, 12-16	16
335	A novel neuroregenerative approach using ET(B) receptor agonist, IRL-1620, to treat CNS disorders. 2018 , 67, S95-S113	17
334	Pursuing the Complexity of Alzheimer's Disease: Discovery of Fluoren-9-Amines as Selective Butyrylcholinesterase Inhibitors and -Methyl-d-Aspartate Receptor Antagonists. 2020 , 11,	3
333	Using machine intelligence to uncover Alzheimer's disease progression heterogeneity. 2020 , 1,	1
332	Challenges in understanding the structure/activity relationship of $A\beta$ oligomers. 2019 , 6, 1-22	2
331	ApoE2 and Alzheimer's disease: time to take a closer look. 2016 , 11, 412-3	39
330	Modulation of mitochondrial bioenergetics as a therapeutic strategy in Alzheimer's disease. 2018 , 13, 19-25	40
329	Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis. 2019 , 14, 1643-1650	30
328	Stem cell therapy for Alzheimer's disease. 2020 , 12, 787-802	30
327	An Alternate View of Neuroprotection with Peptides in Alzheimer's Disease.	1
326	Neuroprotective Potentials of <i>Cocculus hirsutus</i> Leaf Extract Against 6,7-Epoxytropine Tropate-Induced Memory Impairment in Rats. 2021 , 14, 1551-1559	

- 325 Lactobacillus plantarum PS128 prevents cognitive dysfunction in Alzheimer's disease mice by modulating propionic acid levels, glycogen synthase kinase 3 beta activity, and gliosis. **2021**, 21, 259 2
- 324 A Network-based Deep Learning Framework Catalyzes GWAS and Multi-Omics Findings to Biology and Drug Repurposing for Alzheimer's Disease.
- 323 Association of peripheral blood DNA methylation level with Alzheimer's disease progression. **2021**, 13, 191 5
- 322 Salpyran: A Cu(II) Selective Chelator with Therapeutic Potential. **2021**, 60, 15310-15320
- 321 Novel API Coated Catheter Removes Amyloid- β from Plasma of Patients with Alzheimer's Disease. **2021**, 7,
- 320 Automatic Prediction of Cognitive and Functional Decline Can Significantly Decrease the Number of Subjects Required for Clinical Trials in Early Alzheimer's Disease. **2021**, 84, 1071-1078 0
- 319 Nanomaterials for neurodegenerative diseases: Molecular mechanisms guided design and applications. 1
- 318 Uncovering Disease Mechanisms in a Novel Mouse Model Expressing Humanized APOE ϵ and Trem2^{R47H}. **2021**, 13, 735524 2
- 317 A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials. **2021**, 200, 111589 0
- 316 L'innovation thérapeutique : Évolution et tendances. **2015**,
- 315 Protective Effect of Wheat Bran Extract against β Amyloid-induced Cell Death and Memory Impairment. **2015**, 30, 67-75 2
- 314 Stratégie de recherche translationnelle sur la maladie d'Alzheimer : cibles, modèles animaux et biomarqueurs. **2015**, 199, 893-908
- 313 Recent Update of Clinical Drug Trials in Alzheimer's Disease. **2015**, 33, 252-258
- 312 25+ Observations Over 25+ Years for Surviving and Thriving in the Dietary Supplement Quality Control and/or Perception Versus Reality World. **2016**, 5-67
- 311 Effect of flumazenil on memory retrieval determined by trial-to-criteria inhibitory avoidance method in mice. **2016**, 7, 24-6
- 310 Encyclopedia of Geropsychology. **2016**, 1-13
- 309 Could Stem Cells Be Used to Treat or Model Alzheimer's Disease?. **2016**, 203-225 0
- 308 Encyclopedia of Geropsychology. **2017**, 256-268

- 307 What Is Value?. **2017**, 135-149
- 306 Does size matter? The relationship between predictive power of single-subject morphometric networks to spatial scale and edge weight. 2
- 305 A blood-based signature of cerebral spinal fluid A β 42 status. 1
- 304 Computational Modeling of Drugs for Alzheimer's Disease: Design of Serotonin 5-HT₆ Antagonists. **2018**, 419-461
- 303 Transcriptional dysregulation study reveals a core network involving the genesis for Alzheimer's disease.
- 302 Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease. 1
- 301 Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?. **2018**, 1-13
- 300 NEW NOOTROPIC PREPARATION FROM BLOOD PLASMA (ADEMENT): LACK OF THERAPEUTIC INFLUENCE ON DROSOPHILA NEURODEGENERATIVE MODEL. **2018**, 76-82
- 299 The virtual cognitive health (VC Health) study: design, recruitment, and baseline characteristics of a fully remote single-arm pre-post study to prevent or delay cognitive impairment in older adults (Preprint).
- 298 A human embryonic stem cell model of A β -dependent chronic progressive neurodegeneration. 0
- 297 The pathological hallmarks of Alzheimer's disease derive from compensatory responses to NMDA receptor insufficiency.
- 296 Alzheimer's Disease - Clinical Trials. 8,
- 295 Art-Science Collaborations: How to Break Boundaries Without Breaking Trust. **2019**, 43-52
- 294 Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis. **2019**, 4, 3
- 293 Amyloid Beta. **2019**, 235-251 1
- 292 Methodological Foundations of Clinical Research. **2019**, 49-85
- 291 Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. **2019**, 1-119
- 290 Molecular estimation of neurodegeneration pseudotime in older brains. 1

- 289 Collagen hydrogel confinement of amyloid- β accelerates aggregation and reduces cytotoxic effects. 1
- 288 Alzheimer Hastalığı Tedavisinde Kullanılan İlaçlar ve Yeni Yaklaşımlar.
- 287 Predicting the potency of anti-Alzheimer drug combinations using machine learning.
- 286 Measuring brain integrity using MRI: a novel biomarker for Alzheimer's disease using T2 relaxometry. 1
- 285 Early Prediction of Alzheimer's Disease and Related Dementias Using Electronic Health Records.
- 284 An EEG Emotion Classification System Based on One-Dimension Convolutional Neural Networks and Virtual Reality. **2021**, 194-202
- 283 Does Alzheimer's disease stem in the gastrointestinal system?. **2021**, 287, 120088 2
- 282 Downstream Processes. **2020**, 105-136
- 281 Current and Future of Alzheimer's Therapy with the Best Approach. **2020**, 19, 691-697
- 280 Memory Enhancing Activity of Saraswatarishta in Mice. **2020**, 13, 2033-2039
- 279 Targeting Alzheimer's disease and related dementias with CRISPR and human pluripotent stem cell technologies. **2022**, 65-80
- 278 5-YEAR DYNAMIC PREDICTION OF DEMENTIA USING REPEATED MEASURES OF COGNITIVE TESTS AND A DEPENDENCY SCALE. **2021**,
- 277 Tapping into the Potential of Cinnamon as a Therapeutic Agent in Neurological Disorders and Metabolic Syndrome. **2020**, 273-305
- 276 Linking histone deacetylases and phosphodiesterase 5 in novel treatments for Alzheimer's disease. **2020**, 213-226
- 275 Identification and Prediction of Alzheimer Based on Biomarkers Using Machine Learning **2020**, 271-284
- 274 Neuroprotective Compounds from Plant Sources and their Modes of Action: An Update. **2020**, 417-440 2
- 273 Human iPSC-Derived Neurons as A Platform for Deciphering the Mechanisms behind Brain Aging. **2021**, 9, 0
- 272 T2 heterogeneity as an in vivo marker of microstructural integrity in medial temporal lobe subfields in ageing and mild cognitive impairment.

271	Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Ready for Short-term and Long-term Clinical Trial Needs. 2017 , 14, 22-29	24
270	A Novel Therapy for Huntington's Disease. 2018 , 2018,	
269	Identification of Circulating and Exchanges in The Serum of Alzheimer's Patients and Insights into The Pathophysiological Pathways. 2021 , 23, 211-217	
268	Ageing and Alzheimer's Disease. 2021 , 1-16	
267	Human induced pluripotent stem cell-derived astrocytes progenitors as discovery platforms. 2022 , 45-89	
266	Current Research on Pro-Drug Therapies for Parkinson's and Alzheimer's Disease. 2021 ,	
265	Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia. 2021 , 17, 1855-1867	2
264	Glutamyl-Transpeptidase-Resistant Glutathione Analog Attenuates Progression of Alzheimer's Disease-like Pathology and Neurodegeneration in a Mouse Model. 2021 , 10,	1
263	Unraveling the drug distribution in brain enabled by MALDI MS imaging with laser-assisted chemical transfer. 2021 ,	0
262	Microdissected Pyramidal Cell Proteomics of Alzheimer Brain Reveals Alterations in Creatine Kinase B-Type, 14-3-3- η and Heat Shock Cognate 71. 2021 , 13, 735334	
261	NMR Studies of Tau Protein in Tauopathies. 2021 , 8, 761227	0
260	Dietary Regulation of Gut-Brain Axis in Alzheimer's Disease: Importance of Microbiota Metabolites. 2021 , 15, 736814	0
259	Pursuit of precision medicine: Systems biology approaches in Alzheimer's disease mouse models. 2021 , 161, 105558	3
258	Hydromethylthionine enhancement of central cholinergic signalling is blocked by rivastigmine and memantine. 2021 ,	0
257	OUP accepted manuscript.	1
256	The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.. 2022 , 27,	3
255	Can Exercise Training Teach Us How to Treat Alzheimer's disease?. 2022 , 75, 101559	0
254	JOTROL, a Novel Formulation of Resveratrol, Shows Beneficial Effects in the 3xTg-AD Mouse Model.. 2022 ,	0

253	FeO@polydopamine nanoparticle-loaded human umbilical cord mesenchymal stem cells improve the cognitive function in Alzheimer's disease mice by promoting hippocampal neurogenesis. 2021 , 102507	0
252	X-Ray diffraction structure of Cu(II) and Zn(II) complexes of 8-aminoquinoline derivatives (TDMQ), related to the activity of these chelators as potential drugs against Alzheimer's disease. 2022 , 1251, 132078	
251	Investigation of Experimental and In Silico Physicochemical Properties of Thiazole-Pyridinium Anti-Acetylcholinesterase Derivatives with Potential Anti-Alzheimer's Activity. 2020 , 27, 366-377	2
250	Remembering your A, B, C's: Alzheimer's disease and ABCA1.. 2022 , 12, 995-1018	0
249	Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults.. 2022 , 9, 297-305	
248	Integrating Transcriptomics, Genomics, and Imaging in Alzheimer's Disease: A Federated Model. 2022 , 1,	
247	Poor sleep quality is negatively associated with low cognitive performance in general population independent of self-reported sleep disordered breathing.. 2022 , 22, 3	1
246	2-(4-Hydroxyphenyl)benzothiazole dicarboxylate ester TACN chelators for Cu PET imaging in Alzheimer's disease.. 2021 ,	1
245	Design and evaluation of nanostructured lipid carriers loaded with Salvia officinalis extract for Alzheimer's disease treatment.. 2022 ,	1
244	Review of Current Strategies for Delivering Alzheimer's Disease Drugs Across the Blood-Brain Barrier. 2022 , 20, 117-136	
243	Differences in Immune-Related Genes Underlie Temporal and Regional Pathological Progression in 3xTg-AD Mice.. 2022 , 11,	0
242	Harnessing plant biotechnology-based strategies for in vitro galanthamine (GAL) biosynthesis: a potent drug against Alzheimer's disease. 2022 , 149, 81	0
241	Necrostatin-1 Relieves Learning and Memory Deficits in a Zebrafish Model of Alzheimer's Disease Induced by Aluminum.. 2022 , 40, 198	1
240	Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.. <i>Alzheimer's Research and Therapy</i> , 2022 , 14, 7	9 3
239	DOTA: Deep Learning Optimal Transport Approach to Advance Drug Repositioning for Alzheimer's Disease.. 2022 , 12,	0
238	Diet-induced Alzheimer's-like syndrome in the rabbit.. 2022 , 8, e12241	0
237	The 40-Hz White Light-Emitting Diode (LED) Improves the Structure-Function of the Brain Mitochondrial KATP Channel and Respiratory Chain Activities in Amyloid Beta Toxicity.. 2022 , 1	0
236	Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019.. 2022 ,	95

235	Theta band-power shapes amyloid-driven longitudinal EEG changes in pre-clinical Alzheimer's Disease.	0
234	Public opinion regarding U.S. Food and Drug Administration approval of aducanumab and potential policy responses: A nationally representative survey.. 2022 ,	3
233	Machine learning prediction and tau-based screening identifies potential Alzheimer's disease genes relevant to immunity.. 2022 , 5, 125	2
232	Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. 2021 , 22,	3
231	Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease.. 2021 , 1, 1175-1188	13
230	A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome. 2021 , 22,	4
229	Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials.. 2022 , 8, e12223	
228	Engineered Nanomaterials as Drug Delivery Systems and Biomedicines. 2022 , 1-27	
227	Liquid crystalline lipid nanoparticles for combined delivery of curcumin, fish oil and BDNF: In vitro neuroprotective potential in a cellular model of tunicamycin-induced endoplasmic reticulum stress. 2022 , 3, 274-288	3
226	Recent Advancements in Omega Fatty Acids to Treat Neurodegeneration. 2022 , 121-137	0
225	Olive polyphenols and bioavailable glutathione: Promising results in patients diagnosed with mild Alzheimer's disease.. 2022 , 8, e12278	
224	Structure-activity relationship and bioactivity studies of neurotrophic -banglene.. 2022 ,	
223	Locus coeruleus in the pathogenesis of Alzheimer's disease: A systematic review.. 2022 , 8, e12257	0
222	New Perspectives for Treatment in Alzheimer's Disease. 2022 , 199-225	
221	Aging and Alzheimer's Disease. 2022 , 1057-1072	
220	Probing Fluorinated Motifs onto Dual AChE-MAO B Inhibitors: Rational Design, Synthesis, Biological Evaluation, and Early-ADME Studies.. 2022 ,	1
219	Helminth and Host Crosstalk: New Insight Into Treatment of Obesity and Its Associated Metabolic Syndromes.. 2022 , 13, 827486	0
218	Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. 2022 , 23,	3

217	Potential Applications of Artificial Intelligence in Clinical Trials for Alzheimer's Disease.. 2022 , 12,	2
216	Optogenetics: implications for Alzheimer's disease research and therapy.. 2022 , 15, 20	1
215	Financing Alzheimer's Disease Drug Development. 2022 , 465-479	0
214	Exploring common genetic contributors to neuroprotection from amyloid pathology.. 2022 , 4, fcac066	1
213	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. 2022 , 1-24	1
212	Introduction to Venture Capital in Alzheimer's Disease Drug Development. 2022 , 524-532	
211	The Harrington Discovery Institute and Alzheimer's Disease Drug Development. 2022 , 45-53	
210	Artificial Intelligence in Alzheimer's Drug Discovery. 2022 , 62-72	
209	Role of Animal Models in Alzheimer's Disease Drug Development. 2022 , 73-94	
208	Finding Cures for Alzheimer's Disease. 2022 , 51-83	
207	Intrathecal amyloid-beta oligomer administration increases tau phosphorylation in the medial temporal lobe in the African green monkey: a nonhuman primate model of Alzheimer's disease.. 2022 ,	1
206	From synapses to circuits and back: bridging levels of understanding in animal models of Alzheimer disease.. 2022 ,	0
205	Phase-In to Phase-Out-Targeted, Inclusive Strategies Are Needed to Enable Full Replacement of Animal Use in the European Union.. 2022 , 12,	0
204	Therapeutic Opportunities and Delivery Strategies for Brain Revascularization in Stroke, Neurodegeneration, and Aging.. 2022 , 74, 439-461	2
203	Alzheimer's disease - the journey of a healthy brain into organ failure.. 2022 , 17, 18	3
202	Valley of Death and the Role of Venture Philanthropy in Alzheimer's Disease Drug Development. 2022 , 480-485	
201	Protective Effect of Human-Neural-Crest-Derived Nasal Turbinate Stem Cells against Amyloid- β Neurotoxicity through Inhibition of Osteopontin in a Human Cerebral Organoid Model of Alzheimer's Disease.. 2022 , 11,	1
200	Solving neurodegeneration: common mechanisms and strategies for new treatments.. 2022 , 17, 23	5

199	Progress and Development of Carbazole Scaffold based as Potential Anti-Alzheimer Agents using MTDL Approach.. 2022 , 19,	1
198	Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer’s Disease Drug Discovery. 2022 , 106-122	
197	Cognitive Training Modulates Brain Hypersynchrony in a Population at Risk for Alzheimer’s Disease.. 2022 , 86, 1185-1199	
196	Promising heterocycle-based scaffolds in recent (2019-2021) anti-Alzheimer’s drug design and discovery.. 2022 , 174847	1
195	Ginkgolides and Huperzine A for complementary treatment of Alzheimer’s disease.. 2022 ,	1
194	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.. 2022 ,	2
193	HMTM-Mediated Enhancement of Brain Bioenergetics in a Mouse Tauopathy Model Is Blocked by Chronic Administration of Rivastigmine.. 2022 , 10,	
192	Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents.. 2022 , 5, e226567	0
191	Strain-specific pre-existing immunity: A key to understanding the role of chronic Toxoplasma infection in cognition and Alzheimer’s diseases?. 2022 , 104660	0
190	Anti-neurodegenerative benefits of acetylcholinesterase inhibitors in Alzheimer’s disease: Nexus of cholinergic and nerve growth factor dysfunction.. 2021 ,	1
189	Thermogravimetric infrared analysis for the pyrolysis mechanism and shelf life of lycoramine hydrobromide. 2022 , 54, 133-141	0
188	The 677C>T variant in methylenetetrahydrofolate reductase causes morphological and functional cerebrovascular deficits in mice.	0
187	Association of CSF A β 8 Levels With Risk of Alzheimer Disease-Related Decline.. 2021 ,	2
186	Alzheimer’s Disease: Current Perspectives and Advances in Physiological Modeling.. 2021 , 8,	1
185	Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias.. 2021 ,	0
184	Differential Identification of Prodromal Stages of Alzheimer’s Disease Using Tissue Probability Map (TPM) based Network. 2021 ,	0
183	Assessing Causal Relationship Between Human Blood Metabolites and Five Neurodegenerative Diseases With GWAS Summary Statistics.. 2021 , 15, 680104	0
182	Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function. 2021 , 143, 179	6

- 181 Closing the Gap between Observational Research and Randomized Controlled Trials for Prevention of Alzheimer's Disease and Dementia.. **2022**,
- 180 Rational designing of oscillatory rhythmicity for memory rescue in plasticity-impaired learning networks.. **2022**, 39, 110678 1
- 179 Behavioral Interventions in Mild Cognitive Impairment (MCI): Lessons from a Multicomponent Program.. **2022**, 1 0
- 178 Diagnostic Performance of Generative Adversarial Network-Based Deep Learning Methods for Alzheimer's Disease: A Systematic Review and Meta-Analysis.. **2022**, 14, 841696 0
- 177 Combinations of drug candidate properties affecting development success and discontinuation for five diseases: Lymphoma, non-small cell lung cancer, arthritis, depression, and Alzheimer's disease.. **2022**,
- 176 In Silico Screening of Natural Compounds for Candidates 5HT6 Receptor Antagonists against Alzheimer's Disease.. **2022**, 27, 1
- 175 Presentation_1.pdf. **2018**,
- 174 Table_2.XLSX. **2018**,
- 173 Table_3.XLSX. **2018**,
- 172 Table_4.XLSX. **2018**,
- 171 Table_5.XLSX. **2018**,
- 170 Image_1.tif. **2020**,
- 169 Image_2.TIF. **2020**,
- 168 Image_3.TIF. **2020**,
- 167 Image_4.TIF. **2020**,
- 166 Presentation_1.pptx. **2018**,
- 165 Data_Sheet_1.PDF. **2019**,
- 164 Data_Sheet_2.PDF. **2019**,

163 Data_Sheet_3.PDF. 2019,

162 Data_Sheet_4.PDF. 2019,

161 Data_Sheet_5.PDF. 2019,

160 Data_Sheet_6.PDF. 2019,

159 Data_Sheet_7.PDF. 2019,

158 Data_Sheet_8.PDF. 2019,

157 Presentation_1.pdf. 2019,

156 Table_1.XLSX. 2019,

155 Table_2.XLSX. 2019,

154 Table_3.XLSX. 2019,

153 Table_4.XLSX. 2019,

152 Table_5.XLSX. 2019,

151 Table_6.XLSX. 2019,

150 Table_7.XLSX. 2019,

149 Table_8.XLSX. 2019,

148 Data_Sheet_1.docx. 2019,

147 Data_Sheet_1.docx. 2019,

146 Table_1.XLSX. 2019,

145 Table_2.xlsx. **2019**,

144 Table_3.xlsx. **2019**,

143 Table_4.XLSX. **2019**,

142 Table_5.XLSX. **2019**,

141 Data_Sheet_1.pdf. **2018**,

140 Table_1.pdf. **2018**,

139 Table_2.xlsx. **2018**,

138 Table_3.xlsx. **2018**,

137 Table_4.xlsx. **2018**,

136 Table_5.xlsx. **2018**,

135 Table_6.xlsx. **2018**,

134 Table_7.xlsx. **2018**,

133 Data_Sheet_1.XLSX. **2018**,

132 Table_1.XLSX. **2020**,

131 Table_2.XLSX. **2020**,

130 Table_3.XLSX. **2020**,

129 Table_4.XLSX. **2020**,

128 Table_5.XLSX. **2020**,

127	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.. 2022 , 1	2
126	Induced pluripotent stem cell-based organ-on-a-chip as personalized drug screening tools: A focus on neurodegenerative disorders.. 2022 , 13, 20417314221095339	0
125	Combination Therapy in Alzheimer's Disease: Is It Time?. 2022 ,	0
124	Practice Effects in Mild Cognitive Impairment Increase Reversion Rates and Delay Detection of New Impairments.. 2022 , 14, 847315	1
123	Role of Intracellular Amyloid β s Pathway Modulator, Biomarker, and Therapy Target.. 2022 , 23,	4
122	The aging immune system in Alzheimer's and Parkinson's diseases.. 2022 , 1	1
121	Green tea, epigallocatechin gallate and the prevention of Alzheimer's disease: Clinical evidence. 2022 , 11, 765-770	0
120	Bibliographie. 2022 , 279-288	
119	Redox modulation of stress resilience by <i>Crocus Sativus</i> L. for potential neuroprotective and anti-neuroinflammatory applications in brain disorders: From molecular basis to therapy. 2022 , 111686	0
118	Social and Private Costs of Dementia. 2022 , 267-289	
117	Butyrylcholinesterase inhibitors as potential anti-Alzheimer's agents: an updated patent review (2018-present).	0
116	Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models. 2022 , 5,	0
115	BDNF Val66Met Moderates the Effects of Hypertension on Executive Functioning in Older Adults Diagnosed with aMCI. 2022 ,	
114	Liposomes: An emerging carrier for targeting Alzheimer's and Parkinson's Diseases. 2022 , e09575	0
113	Global estimates on the number of persons across the Alzheimer's disease continuum.	5
112	A description of the MEDIA study: A Method for Evaluating Digital endpoints In Alzheimer's disease (Preprint).	
111	Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation. 2022 ,	1
110	Regulation and roles of RNA modifications in aging-related diseases.	2

109	Therapeutic nanotechnologies for Alzheimer's disease: a critical analysis of recent trends and findings. 2022 , 114397	1
108	Chrysin-Loaded Chitosan Nanoparticle-Mediated Neuroprotection in A β 2-Induced Neurodegenerative Conditions in Zebrafish.	0
107	Microglia: Friend and foe in tauopathy. 2022 , 216, 102306	0
106	Exploring the zinc-related transcriptional landscape in Alzheimer's disease. 2022 , 13, 31-37	0
105	Measurement of neurodegeneration using a multivariate early frame amyloid PET classifier. 2022 , 8,	
104	Self-Assembled Nanoscale Materials for Neuronal Regeneration: A Focus on BDNF Protein and Nucleic Acid Biotherapeutic Delivery. 2022 , 12, 2267	2
103	Is Ketogenic Diet Therapy a Remedy for Alzheimer's Disease or Mild Cognitive Impairments?: A Narrative Review of Randomized Controlled Trials. 2022 , 12, 200-208	
102	Strong and reliable synaptic communication between pyramidal neurons in adult human cerebral cortex.	0
101	Artificial intelligence and machine-learning approaches in structure and ligand-based discovery of drugs affecting central nervous system.	0
100	Establishment of autaptic culture with human induced pluripotent stem cell-derived astrocytes. 2022 , 104762	
99	From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases. 13,	
98	Access to new phosphonate- and imidazolidine-benzopyrimidinone derivatives as antityrosinase and anti-acetylcholinesterase agents: Design, synthesis and molecular docking. 2022 , 133693	1
97	The Key Role of Magnetic Resonance Imaging in the Detection of Neurodegenerative Diseases-Associated Biomarkers: A Review.	
96	Differential disruptions in population coding along the dorsal-ventral axis of CA1 in the APP/PS1 mouse model of A β pathology.	
95	Review on the roles of specific cell-derived exosomes in Alzheimer's disease. 16,	1
94	Is There a Connection between the Metabolism of Copper, Sulfur, and Molybdenum in Alzheimer's Disease? New Insights on Disease Etiology. 2022 , 23, 7935	
93	Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study.	1
92	Influenza vaccination and dementia risk; an unanticipated benefit?. 2022 , 80, 104187	

- 91 Goal-directed action is transiently impaired in an hAPP-J20 mouse model of Alzheimer’s disease, and in aging male mice regardless of genotype.
- 90 Phase 2. **2022**, 149-168
- 89 Pharmacological activation of the C5a receptor leads to stimulation of the β adrenergic receptor and alleviates cognitive impairment in a murine model of familial Alzheimer’s disease. 13,
- 88 A 5-year community program in Singapore to prevent cognitive decline. ○
- 87 Therapeutic roles of plants for 15 hypothesised causal bases of Alzheimer’s disease. **2022**, 12, ○
- 86 Novel 3-aminobenzofuran derivatives as multifunctional agents for the treatment of Alzheimer’s disease. 10, 1
- 85 A Contextual-Bandit-Based Approach for Informed Decision-Making in Clinical Trials. **2022**, 12, 1277
- 84 EURL ECVAM Literature Review Series on Advanced Non-Animal Models for Respiratory Diseases, Breast Cancer and Neurodegenerative Disorders. **2022**, 12, 2180
- 83 The causes and consequences of Alzheimer’s disease: phenome-wide evidence from Mendelian randomization. **2022**, 13, ○
- 82 Association between Human Blood Metabolome and the Risk of Alzheimer’s Disease. ○
- 81 Systems pharmacology and pharmacokinetics strategy to decode bioactive ingredients and molecular mechanisms from *Zingiber officinale* as Phyto-therapeutics against neurological diseases. **2022**, 19,
- 80 Exercise engagement drives changes in cognition and cardiorespiratory fitness after 8 weeks of aerobic training in sedentary aging adults at risk of cognitive decline. 3, ○
- 79 Alzheimer’s disease failed clinical trials. **2022**, 306, 120861 2
- 78 Theta Band-Power Shapes Amyloid-Driven Longitudinal EEG Changes in Elderly Subjective Memory Complainers At-Risk for Alzheimer’s Disease. **2022**, 1-16 ○
- 77 Placing behaviour at the forefront of brain science. **2022**, 142, 104861 ○
- 76 An Update on Treatment of Cognitive Impairment Associated with Schizophrenia. **2022**, ○
- 75 Therapeutic Potential of PPARs in Alzheimer’s Disease. **2022**, 387-415 ○
- 74 Polypharmacology in Drug Design and DiscoveryBasis for Rational Design of Multitarget Drugs. **2022**, 397-533 ○

- 73 Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer's disease: protocol for the ExPlas study. **2022**, 12, e056964 0
- 72 Dementia clinical trials over the past decade: are women fairly represented?. **2022**, 4, e000261 0
- 71 Elevated ganglioside GM2 activator (GM2A) in human brain tissue reduces neurite integrity and spontaneous neuronal activity. **2022**, 17, 0
- 70 Introduction of a pharmacological neurovascular uncoupling model in rats based on results of mice. **2022**, 0
- 69 iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine. **2022**, 12, 1485 0
- 68 Early detection of Alzheimer's disease using neuropsychological tests: a predict-diagnose approach using neural networks. **2022**, 9, 0
- 67 Cryptotanshinone Alleviates Oxidative Stress and Reduces the Level of Abnormally Aggregated Protein in Caenorhabditis elegans AD Models. **2022**, 23, 10030 0
- 66 The 677C > T variant in methylenetetrahydrofolate reductase causes morphological and functional cerebrovascular deficits in mice. 0271678X2211226 1
- 65 Genetic correlations between gut microbiota genera and Alzheimer's Disease. 0
- 64 A Bioinformatics Analysis Reveals that the Transcription Levels of Cell Surface Receptor Encoding Genes are Associated with the Drug Response of Breast Cancer Cells and the Drug Off-Target Effects. 0
- 63 A deep learning model for detection of Alzheimer's disease based on retinal photographs: a retrospective, multicentre case-control study. **2022**, 3
- 62 Association between physical activity and mild cognitive impairment in community-dwelling older adults: Depression as a mediator. 14, 0
- 61 Neurocognitive trajectory and proteomic signature of inherited risk for Alzheimer's disease. **2022**, 18, e1010294 0
- 60 Increased KIF11/Kinesin-5 expression offsets Alzheimer A β -mediated toxicity and cognitive dysfunction. **2022**, 105288 0
- 59 The Alzheimer's Cell Atlas (TACA): A single-cell molecular map for translational therapeutics accelerator in Alzheimer's disease. **2022**, 8, 0
- 58 Experimentation and Approval Mechanisms. **2022**, 90, 2215-2247 3
- 57 Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study. 0
- 56 Naturally occurring Alzheimer's disease in rhesus monkeys. 0

55	It's Groundhog Day! What Can the History of Science Say About the Crisis in Alzheimer's Disease Research?. 2022 , 1-15	1
54	Carnosic Acid Attenuates A β s-Induced Apoptosis and Synaptic Impairment via Regulating NMDAR2B and Its Downstream Cascades in SH-SY5Y Cells.	2
53	Clinical Data Interchange Standards in Clinical Trials on Alzheimer's Disease. 2022 , 19, 814-823	0
52	Proteomics Evidence of the Role of TDMQ20 in the Cholinergic System and Synaptic Transmission in a Mouse Model of Alzheimer's Disease. 2022 , 13, 3093-3107	1
51	Guanidine-based β -amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review. 2022 , 74, 117047	1
50	Cognitive Performance following Single- or Multi-Session Exercise Intervention in Middle Age: A Systematic Review. 1-37	0
49	Polygenic risk scores: An overview from bench to bedside for personalised medicine. 13,	1
48	Population-based discovery and Mendelian randomization analysis identify telmisartan as a candidate medicine for Alzheimer's disease in African Americans.	1
47	Repeated performance of spatial memory tasks ameliorates cognitive decline in APP/PS1 mice. 2022 , 114218	0
46	Multiple Actions of H ₂ S-Releasing Peptides in Human β -Amyloid Expressing C. elegans.	0
45	Therapeutic Potential of Targeting Mitochondria for Alzheimer's Disease Treatment. 2022 , 11, 6742	0
44	Dual-targeted repetitive transcranial magnetic stimulation modulates brain functional network connectivity to improve cognition in mild cognitive impairment patients. 13,	0
43	Infectious origin of Alzheimer's disease: Amyloid beta as a component of brain antimicrobial immunity. 2022 , 18, e1010929	2
42	Epidemiology of neurodegenerative diseases in the East African region: A meta-analysis. 13,	0
41	Prelimbic Cortical Stimulation with L-methionine Enhances Cognition through Hippocampal DNA Methylation and Neuroplasticity Mechanisms. 2022 , 0	2
40	Amyloid Cascade Hypothesis for the Treatment of Alzheimer's Disease: Progress and Challenges. 2022 , 13, 1745	1
39	Stakeholders' Perspectives on Preclinical Testing for Alzheimer's Disease. 2015 , 26, 297-306	3
38	A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. 2022 , 12, 2975	1

37	Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease. 2022 , 41, 111717	0
36	Upregulation of Ca ²⁺ -binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer's disease in Tg2576 mice. 2022 , 17,	0
35	A review of therapeutic failures in late-stage clinical trials. 1-11	0
34	Distribution in Rat Blood and Brain of TDMQ20, a Copper Chelator Designed as a Drug-Candidate for Alzheimer's Disease. 2022 , 14, 2691	1
33	A metabolite attenuates neuroinflammation, synaptic loss and cognitive deficits induced by chronic infection of <i>Toxoplasma gondii</i> . 13,	0
32	Genetic correlations between gut microbiome genera, Alzheimer's disease diagnosis, and APOE genotypes: a polygenic risk score study.	0
31	Brain organoid-on-a-chip: A next-generation human brain avatar for recapitulating human brain physiology and pathology. 2022 , 16, 061301	1
30	How far is the goal of applying β -amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer's disease with standardization of measurements?. 2022 ,	0
29	Donanemab for Alzheimer's Disease: A Systematic Review of Clinical Trials. 2023 , 11, 32	0
28	Molecular insights into sex-specific metabolic alterations in Alzheimer's mouse brain using multi-omics approach. 2023 , 15,	0
27	A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease. 2023 , 29,	2
26	A blood-based panel of DNA methylation markers improves diagnosis accuracy of Alzheimer's disease.	0
25	Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease.	0
24	Update on Alzheimer's Disease. 82-90	0
23	Role of Metal Cations of Copper, Iron, and Aluminum and Multifunctional Ligands in Alzheimer's Disease: Experimental and Computational Insights. 2023 , 8, 4508-4526	0
22	Into the Wild: Reflecting on Neuroethics as Innovation Moves from the Laboratory to Society. 2023 , 195-208	0
21	Goal-directed action is transiently impaired in a hAPP-J20 mouse model of Alzheimer's disease. ENEURO.0363-22.2023	0
20	Rey auditory verbal learning test in idiopathic normal pressure hydrocephalus and Alzheimer's disease. 1-17	0

- 19 Liquid-liquid phase separation of protein tau: An emerging process in Alzheimer's disease pathogenesis. **2023**, 178, 106011
- 18 A Genetically Heterogeneous Rat Model with Divergent Mitochondrial Genomes.
- 17 Therapeutic potential of extracellular vesicles in neurodegenerative disorders. **2023**, 243-266
- 16 Oxidation of TDMQ20, a Specific Copper Chelator as Potential Drug Against Alzheimer's Disease. **2023**, 8,
- 15 Early prediction of Alzheimer's disease and related dementias using real-world electronic health records.
- 14 Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trial. **2023**, 15,
- 13 Neuroprotective effect of angiotensin II receptor blockers on the risk of incident Alzheimer's disease: A nationwide population-based cohort study. 15,
- 12 Poor Translatability of Biomedical Research Using Animals – A Narrative Review. **2023**, 51, 102-135
- 11 A Comparative Exploration of Machine Learning Algorithms for Disease Detection. **2022**,
- 10 The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders. **2023**, 255-285
- 9 Brain FDG PET for visualizing the relation between impaired lung function and cognitive decline in lung cancer: a preliminary study. Publish Ahead of Print,
- 8 Alzheimer's Disease and Stem Cell Therapy. 36, 499-508
- 7 Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases. **2023**, 39-70
- 6 Exploiting butyrylcholinesterase inhibitors through a combined 3-D pharmacophore modeling, QSAR, molecular docking, and molecular dynamics investigation. **2023**, 13, 9513-9529
- 5 Exploiting machine learning models to identify novel Alzheimer's disease biomarkers and potential targets. **2023**, 13,
- 4 Association of retinal optical coherence tomography metrics and polygenic risk scores with cognitive function and future cognitive decline. bjo-2022-322762
- 3 Genetic correlations between Alzheimer's disease and gut microbiome genera. **2023**, 13,
- 2 Cryo-EM Structures of Amyloid Fibrils from Alzheimer's Disease Mouse Models.

1 Stem cells in the treatment of Alzheimer's disease [Promises and pitfalls. **2023**, 1869, 166712

o